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Cancer is a complex disease driven by somatic genomic alterations (SGAs) that perturb signaling 
pathways and consequently cellular function. Identifying combinatorial patterns of pathway 
perturbations would provide insights into common disease mechanisms shared among tumors, 
which is important for guiding treatment and predicting outcome. However, identifying 
perturbed pathways is challenging, because different tumors can have the same perturbed 
pathways that are perturbed by different SGAs.  
We started off by designing a novel semantic representation that captures the functional 
similarity of distinct SGAs perturbing a common pathway in different tumors. This 
representation was used alongside the nested hierarchical Dirichlet process topic model in order 
to identify combinatorial patterns in altered signaling pathways. We found that the topic model 
was able to capture the functional relationships between topics. It was also able to identify cancer 
subtypes composed of tumors from different tissues of origin that exhibit different survival rates. 
These results led us to investigate the performance of the methodology on pan-cancer 
data, as well as in conjunction with cancer driver data. The results revealed that the framework 
was still able to identify clinically relevant features in pan-cancer. However, the addition of 
driver data decreased the noise in the data and improved the separation of tumors in the 
clustering results. This provided support for including the use of driver data in our methodology. 
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 v 
In order to have gene representations independent of literature, we developed a biological 
representation that could identify functionally related genes. Its performance when used 
alongside topic modeling was tested. We found that the topic association patterns separated 
tumors by their tissue of origin. But, analyzing some of the cancer types on an individual basis 
still led to significant differences in survival. 
Our studies show the potential for using alternative representations in conjunction with 
topic modeling to investigate complex genomic diseases. With further research and refinement of 
this methodology, it has the potential to capture the relationship between pathways involved in 
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Cancer is one of the leading causes of death worldwide, responsible for 8.2 million deaths in 
2012 [1]. It is a disease where abnormal cells have uncontrolled cell growth and division, and is 
able to invade other tissues [2]. There are many different exogenous and endogenous factors 
related to cancer, which may lead to genetic alterations or otherwise impact cellular functions. 
Factors that induce altered cellular functions include viruses [3-5] and chronic inflammation [6-
8]. However, the disease is more often the result of genetic alterations that lead to altered cellular 
function [9, 10]. These may be constitutional or somatic genetic alterations (SGAs). 
Constitutional alterations, which are also referred to as germline alterations, are genetically 
inherited; thus each constitutional alteration is present in every cell. On the other hand, SGAs 
occur after conception and thus each SGA is not present in every cell. While constitutional 
genetic alterations may result in a predisposition towards developing cancer [11-15], inherited 
cancer makes up only a small proportion of the total cancer cases [16]. Most cancers are the 
result of SGAs that are accumulated over time [9]. 
Understanding how SGAs contribute to the development of cancer would shed light on 
the mechanisms that underlie the disease and guide treatment. Currently, cancers are first 
classified by the organ of origin and then further classified into subtypes or grades according to 
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their clinical and/or molecular characteristics [17]. For example, cancers are first classified as 
lung cancer, breast cancer, etc, where breast cancers can be further classified as LumA, LumB, 
Basal and Her2 subtypes according to their molecular characteristics through gene expression 
[18, 19]. Classification according to anatomical location is a natural option from a taxonomic 
perspective, and molecular classification of tumors based on gene expression provides valuable 
clinical information in terms of prognosis. However, current classifications do not reflect the 
underlying disease mechanisms. In other words, current classification of cancers is mainly based 
on the observed phenotype rather the driving causes of the disease. As such, the current 
classifications have limited utility in terms of guiding precision medicine targeting the cause of 
the disease. Here we hypothesize that, by finding the combinatorial patterns of pathway 
perturbations among cancers from different tissue of origin, we may classify cancers according 
to the disease mechanisms. This, in turn, will lead to a better understanding of cancer and better 
therapy. 
1.1.1 Biological Processes of Cancer 
Decades of cancer research revealed that a number of biological processes are involved in the 
development of cancer. Hanahan and Weinberg have summarized these as six different 
hallmarks of cancer (sustained proliferative signaling, evading growth suppressors, tissue 
invasion and metastasis, enabling replicative immortality, sustained angiogenesis, and resisting 
cell death), and more recently added two emerging hallmarks (deregulated metabolism and 
avoiding immune destruction) and two enabling characteristics (tumor-promoting inflammation 
and genome instability and mutation) [7, 10]. The theory is that normal cellular functions need to 
be altered in order to attain these hallmarks and for normal cells to develop into malignant and 
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metastatic tissue. These changes in cellular function are, in turn, the result of altered functions of 
cellular signaling pathways regulating these processes. Alterations of signaling pathways that 
lead to cancer are often the result of SGAs affecting signaling proteins. For example, mutations 
in the RB1 pathway lead to aberrant activation of cell proliferation pathways [20-22], and SGAs 
resulting in aberrant activation of mTOR pathways enable cancer cells to adapt to changed 
nutrition or hypoxic environments [23, 24]. It is believed that different combinations and degrees 
of perturbation of signaling pathways underlying the hallmark processes lead to the 
heterogeneous phenotypes associated with individual tumors.   
Projects such as The Cancer Genome Atlas (TCGA) and the International Cancer 
Genome Consortium have made a large volume of cancer genomic data available. One goal of 
analyzing SGA data is to reveal the pathways perturbed by SGA events and therefore shed light 
on the disease mechanisms of cancers. Analyses of this data have lead researchers to notice that 
the prevalence of distinct SGA varies across different types of cancer, both within and across 
different tissue types [25-34]. For example, it is noted that TP53 mutations are highly prevalent 
in ovarian cancer but relatively infrequent in kidney cancers [25, 31, 35]. Most current TCGA 
publications mainly concentrate on investigating the prevalence of mutations and often report the 
results as a ranked list of most frequently mutated genes.  However, such a list does not reflect 
the combinatorial patterns of SGAs, such as where a set of SGAs commonly co-occurs in a 
subset of tumors, as an indication that these tumors share a common disease mechanism.  It is 
noted that specific combination of SGAs, thereby the combination of perturbed signaling 
pathways, determines the aggressiveness of cancer and its responsiveness to therapy [18, 36]. 
Different combinations of perturbed pathways can occur in cancers from the same organ of 
origin, which is what results in the heterogeneity of cancer [9, 18]. However, to the best of our 
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knowledge, few studies try to develop and apply statistical methods specifically aimed to identify 
combinatorial patterns of SGAs or pathways as a means for discovering distinct disease 
mechanisms underlying heterogeneity of cancers [37, 38]. This is the main task to be addressed 
in this dissertation.   
There are two challenges in detecting patterns in signaling pathway perturbations based 
on genomic alteration data from TCGA or the International Cancer Genome Consortium (ICGC). 
The first of these lies in the fact not all mutations that occur are “driver” mutations that lead to 
the development of cancer. Rather, a cancer cell may have multiple “passenger” mutations that 
do not contribute to cancer development [9, 39, 40]. Thus, it is necessary to be able to distinguish 
between driver and passenger mutations. The second challenge lies in the fact that signaling 
pathways are composed of multiple proteins. It is often the case that perturbing any one of the 
proteins along a pathway would have the same impact on the entire pathway. For example, Ras, 
Raf, MEK and MAPK are all part of the MAPK signaling pathway, and mutating any one of 
these genes would lead to altered cell proliferation [41-44]. As discussed before, this 
phenomenon leads to the apparent high degree of heterogeneity of SGAs, i.e., very few tumors 
share a common set of SGAs even if a common set of pathways are perturbed among them [9, 
18, 45]. This is what makes it difficult to determine that the same signaling pathway is affected 
in different tumors, since different SGAs may be observed. When it is already difficult to 
determine that an individual signaling pathway is perturbed, it becomes even more challenging to 
learn combinations of pathway perturbations directly based on genomic alteration data. In this 
dissertation, we will investigate methods to overcome these challenges and detect patterns in 
pathway perturbations in cancer based on SGAs. 
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1.1.2 Identifying Driver Genes 
As cancer genomic sequencing data became increasingly available, it is now widely appreciated 
that most of the mutations in a cancer sample are passenger mutations and only a few of them are 
driver mutations [7, 35, 46]. It is important to identify driver genes in order to reduce the amount 
of noise when trying to classify cancers. Since identifying driver genes is vital to understanding 
cancer development, many researchers have focused on this problem. Multiple approaches have 
been implemented in order to distinguish between driver mutations and passenger mutations and 
evaluate the resulting identifications. The current driver identification approaches falls under 
three large categories, with each concentrating on one of the following characteristics: frequency 
of gene alteration (recurrence), mutual exclusivity of mutations within a pathway, and functional 
impact of mutations. 
1.1.2.1 Frequency-based approaches for identifying driver genes 
The frequency-based approaches aim to identify the mutations that are observed in a 
population of tumors with a prevalence above random chance determined according to a 
background mutation frequency [35, 39, 47-50]. The assumption is that the mutations that 
increase the chances of cancer developing would occur at a higher prevalence than random 
mutations due to “positive selection”. Thus the mutations that occur at a higher frequency are 
more likely to be driver mutations that result in oncogenic advantages in cancer cells [7, 9, 10]. 
Most of these methods identify driver genes based on somatic mutations [35, 39, 47-50]. 
Although researchers also investigated the landscape of copy number alterations to identify 
cancer driver genes [51], there is no established criterion to determine if a copy number 
alteration of a gene or chromosome region is a driving event.  
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In order to accurately predict which genes are mutated at a higher than expected 
frequency, a background mutation frequency needs to be established. Based on the idea that 
silent mutations do not undergo selective pressure, Greenman et al. implemented one of the most 
basic methods of calculating background mutation frequency by using the rate of silent 
mutations [39]. This method has been used to evaluate mutated genes in both breast cancer and 
across the entire human cancer genome [52, 53]. However, having a one-fit-all background 
mutation rate can result in both false positive and false negative calls for driver mutations. 
Researchers noticed that mutation rate can be highly heterogeneous across the human genome, 
dependent on genome location, sequence patterns (e.g., nucleotide repeats), and transcription 
activity of the region [48, 54]. In order to compensate for the fact that the mutation rate of genes 
isn’t consistent in individual patients or in individual genes, Lawrence et al. introduced an 
adjustment to this calculation by taking into account the patient-specific mutation frequency and 
mutation spectrum, and gene-specific background mutation rates [47, 48]. They implemented 
this method and made it available in the MutSigCV tool [48]. Since it is also possible for 
mutation rates to vary based on the type of mutation, another method of calculating background 
mutation frequency is to separate the mutations into different mutational mechanism categories 
[35, 49, 50]. This is relevant in situations where a certain type of mutation mechanism is more 
common. For example, smoking increases the prevalence of the mutation mechanism G:C-to-
T:A transversions. This means there would be more passenger genes with this type of mutation. 
Thus, a gene with this type of mutation would have to recur at a higher rate in order to be of 
interest when compared to a gene with a different mutation mechanism. The background rate 
was calculated for each mutation mechanism category by dividing the number of mutations in a 
category by the total number of bases where such a mutation can occur [35, 49, 50]. 
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While frequency-based approaches can detect genes that have high mutation frequencies 
as drivers with relatively good accuracy, they are not suited to differentiate between driver and 
passenger mutations that have relatively low frequency. For example, Lawrence et al. examined 
mutation rates and performed saturation analysis using pan-cancer data from TCGA, and they 
concluded that current methods cannot reliably detect drivers if the mutation rate is below 20% 
[47], however over 90% of genes mutated in TCGA samples have a mutation rate below this 
threshold. Even though methods have been developed to better detect the genes that are mutated 
at intermediate frequencies [47], being able to use recurrence to detect driver genes that occur at 
low frequencies remains difficult. 
Cancers can also be driven by somatic copy number alterations (amplification or 
deletion) of certain genes. The best known examples are the copy number alteration of MYC 
[55], ERBB2 (Her2) [56] and PTEN [57]. Her2 amplification is prevalent in breast cancers and is 
associated with specific molecular characteristics, such that a molecular subtype of breast cancer 
is labeled as Her2-positive [19, 58]. While many genes affected by somatic copy number 
variations are classified as drivers through biological experiments, setting a guideline by which 
to detect drivers in copy number variations has been difficult. In order to take steps toward 
detecting drivers, Zack et al. established a way to estimate the background frequency of copy 
number alterations [51]. They did so by calculating the frequency that copy number alteration 
events of similar length and amplitude occur across the entire TCGA dataset, while correcting 
for the length and chromosomal location of the copy number alteration [51]. However, they were 
still unable to set a threshold by which to determine which genes are drivers. 
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1.1.2.2 Finding driver genes on a pathway based on their mutual exclusivity pattern 
Mutation patterns in tumors have been used to identify driver genes or pathways based on 
the characteristic that SGAs affecting members of a common pathway are less likely to co-occur 
in the same tumor, a phenomenon referred to as mutual exclusivity. The explanation for this 
phenomenon is that when a tumor only needs one driver gene to be altered in a driver pathway, 
altering a second driver is unnecessary [45]. Thus, driver genes with the same functional impact 
would tend to, but does not have to, be mutually exclusive. Both somatic gene mutations [45, 49, 
59, 60] and copy number alterations [25, 45, 51, 59] have been used to detect mutual exclusivity. 
One method of determining mutual exclusivity is to calculate the correlation or anticorrelation of 
genes when compared with a background co-occurrence rate [49, 51]. Like the background 
mutation rate, the background co-occurrence rate can be calculated in different ways. Zack et al. 
calculated the background co-occurrence rate for copy number alterations by permuting the copy 
number profiles of chromosomes across samples [51]. When calculating the rate for gene 
mutations, Dees et al. permuted the observed gene mutations, while keeping both the distribution 
of the number of gene mutations per sample and the number of mutations in each gene constant 
[49]. 
Mutual exclusivity can also be identified independent of a background co-occurrence 
rate. Ciriello et al. used gene interaction networks to identify gene subsets that are fully 
connected [60]. These subsets are then assessed for highly recurrent and mutually exclusive 
genes, by comparing to randomly generated networks [60]. The Dendrix algorithm was 
developed to determine mutual exclusivity by identifying genes that have a maximal coverage of 
the tumors while minimizing the overlap of the genes [59]. This has also been extended to 
simultaneously identify multiple driver pathways [45]. 
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Mutual exclusivity is not based on the frequency of alterations, but rather based on the 
assumption that the mutual exclusivity of genes is the result of them being part of the same 
driver pathways. As a result, methods based on mutual exclusivity are capable of detecting driver 
genes that have a lower rate of occurrence. However, there are many other situations that could 
result in genes being mutually exclusive besides being part of the same driver pathway. Since the 
algorithms are unable to differentiate between mutually exclusive drivers and other situations 
that result in mutual exclusivity, this would impact the accuracy of the driver genes predicted by 
these methods [61].  
1.1.2.3 Identifying driver genes using the impact of mutations on individual gene function  
Driver mutations have also been identified by detecting genes hosting mutation events 
that likely affect their function. For example, a gene that is affected by mutations that tend to 
cause loss or gain of function, e.g., truncation mutations or relatively large insertions or 
deletions, or mutations in the evolutionally conserved regions. The theory behind searching for 
driver genes based on the functional impact of their mutation is that driver genes would have 
more mutations with greater functional impact, because drivers need to be altered in order for 
cancer to develop. Many different methods of assessing the functional impact of a mutation have 
been developed. For example, Reva et al. used evolutionary information to predict functional 
impact, with the idea that residues that are evolutionarily conserved are more likely to be 
functional than those that are not conserved [62]. This allows predictions to be made as long as 
protein family sequences are available to generate sequence homologs [62].  
Mutation locations can also be used to assess functional impact. Gain of function genetic 
alterations often cluster together in specific protein regions [63], which can be utilized to detect 
driver genes that undergo gain of function alterations. These genes can be identified by searching 
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for genes with a bias towards having clusters of protein-affecting mutations, when compared to a 
baseline clustering rate. Tamborero et al. used silent mutations as a measure of baseline 
clustering [63], in lieu of using a homogeneous mutation probability [49]. Another location-
based method is to determine the rate of mutation at functional residues. Reimand et al. 
evaluated mutation rates at phosphorylation-sites in order to predict signaling-specific cancer 
driver genes [64]. In this case, the background mutation rates used were non-synonymous 
mutations that were not phosphorylation-related [64].  
These types of functional impact measures can be used to identify the genes that have a 
tendency to accumulate mutations with high functional impact [50]. As such, they are aimed at 
detecting a different set of driver genes than the previous two approaches. The benefit of 
functional impact measures is that they limit the noise incorporated from mutations that do not 
impact function. However, the accuracy of these driver identification methods is limited by the 
accuracy of the functional impact predictions. 
1.1.2.4 Lack of gold standard driver genes 
Despite all the driver identification methods available, the lack of a gold standard of 
knowledge has made the evaluation of these methods limited. The data available that most 
closely approaches a gold standard are cancer driver databases [46, 65]. As such, some driver 
identification methods have been run on these cancer driver databases to determine if they are 
capable of detecting known drivers [62, 63]. These cancer driver databases can also be used as an 
evaluation metric when running the algorithms on cancer datasets. Generally the algorithms are 
run on cancer datasets to identify both known and new cancer genes, with the new genes being 
considered potential novel drivers [35, 39, 45, 47-51, 62-64, 66]. Using the databases to calculate 
a positive predictive proxy measure makes it possible to approximate the positive predictive 
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value of the returned driver gene lists, and compare the results of different methods [50]. 
Another evaluation method that doesn’t require cancer datasets or databases is the use of 
simulated data [45]. Generating artificial data allows researchers to know what the correct 
prediction results should be. However, simulated data are generated to fit the designed algorithm, 
and can be difficult to apply and compare to other algorithms.  
1.1.3 Cancer Subtyping 
Cancers can differ based on many different features, such as the tissue of origin or its disease 
mechanisms. The process of cancer subtyping is to separate cancers based on these features. 
Because these features can have an effect on a cancer’s response to treatment, the resulting 
cancer subtypes respond differently to different treatments. This is why cancer subtyping is an 
important step in the diagnostic process, and plays a role in cancer treatment. Therefore, the goal 
of improving cancer subtyping methods is to improve cancer treatment through precision 
medicine, which will be expanded upon in section 1.1.4. 
Current medical guidelines focus on classifying cancer based on observable features, 
which include the primary site, histology, cell differentiation, and the extent of the disease [17]. 
The primary site, or the location where the cancer is first developed, is used to separate the 
cancer into broad categories, such as breast cancer or lung cancer. This is also used to track 
where a metastasized secondary cancer originated from. Histological features are used to further 
subtype primary cancer. For example, lung cancer can be further separated into small cell lung 
cancer, adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma. Cell differentiation 
is used to grade the tumor and determine its aggressiveness. Tumors that bear a closer 
resemblance to normal tissue would be less aggressive and have a lower grade than those that are 
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poorly differentiated. The extent of the disease can then be used to stage the disease, with tumors 
that have spread further receiving a higher stage.  
In last two decades, molecular features of some cancers have been discovered, allowing 
them to be subtyped further. For example, receptor expression and gene expression can be used 
to further separate breast cancer into basal, HER-2, and luminal A and B tumors [19, 67, 68]. 
The limitation of these current methods is that there are many different genetic alterations that 
can result in these different disease presentations. As a result, the same treatment has different 
degrees of effectiveness in patients with the same cancer subtype. It is important to identify the 
genetic changes that result in these different features, in order to learn what causes the varying 
degrees of treatment response. Contemporary molecular subclassification does not directly 
provide insights into the cellular or disease mechanisms underlying the subtypes or guide 
treatment.   
There has been recent research focusing on separating cancers into different classes based 
on their disease mechanisms, which can be shared across different tissues of origin. The most 
frequently used data types are somatic mutations [35, 37, 38, 69] and copy number alterations 
[38, 69], however other types of expression data are also used [38, 69]. Different clustering 
methods have been applied to these input data in order to separate the tumors into classes. 
Unsupervised hierarchical clustering was directly applied to significantly mutated genes to 
separate the tumors into separate classes based on their mutation patterns [35]. Similarly, 
Hoadley et al. also clustered the tumors based on significantly mutated genes [38]. However, 
they took this process a step further by also clustering by copy number alteration as well as 4 
other data types, which resulted in a total of 6 different clustering results [38]. They then 
separated the tumors into classes by clustering based on 5 clustering results, after excluding 
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somatic mutations from their analysis [38]. This cluster-of-cluster analysis is an effective way to 
combine the input from multiple data types. However, if some of the data types contain 
overlapping information, their combined signal may overpower the signal provided by other data 
types. Thus, care needs to be exercised when selecting and processing the data types used for 
input. Ciriello et al. used somatic mutation, copy number alteration, methylation, and gene 
expression data in order to generate recurrent functional events, which are functional alterations 
that occur at a high frequency [69]. These functional events should contain information about the 
functions altered in a cancer sample. Generating a network where samples and functional events 
are nodes, and samples are connected to events using edges allowed them to represent the 
alterations in each sample. This also makes it possible to use graph clustering to group samples 
with similar alterations into classes [69]. All of the previously listed methods used the altered 
genes directly, and so were unable to represent the fact that different genes can impact the same 
pathway. This restriction makes it difficult to learn the disease mechanisms that lead to the 
development of cancer. 
In order to help identify the disease mechanisms of cancer, signaling pathway 
information should be incorporated. Hofree et al. noticed that mutation data are highly 
heterogeneous among tumors, making it difficult to find mutation patterns [37]. To address this 
problem, they mapped mutations to gene interaction networks as a means to map mutations to 
function space. Then tumors with similar regions in the gene interaction network perturbed can 
be identified, thus stratifying the tumors [37]. While this is a method to represent the functions a 
gene is involved in, it is limited by the accuracy and scope of the gene interaction networks 
available. However, an increased incorporation of pathway perturbation information into cancer 
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subtyping should result in more specific diagnoses and more precise treatment than is currently 
available. 
1.1.4 The need for disease-mechanism-based classification of cancers  
Research that leads to a better understanding of cancer and its disease mechanisms would have 
significant impact in different areas of cancer treatment. Two prominent areas would be in 
precision medicine and drug development. Current methods of cancer classification are based on 
phenotype [17]. While some of the contemporary cancer classifications contain information for 
prognosis, they usually do not provide information about the underlying disease mechanisms. 
This is because the gene expression profile of a tumor reflects a convoluted outcome of all 
cellular signal pathways that actively regulate expression in tumor cells. Therefore, it is difficult 
to map a profile to the activation states of individual pathways.  However, if we can identify the 
SGAs that underlie a specific gene expression profile, the results will shed light on the disease 
mechanisms of a tumor.   
The idea behind precision medicine is to tailor treatment to an individual patient using 
patient-specific information, including their genomic data. The critical task is to understand how 
perturbations of signaling pathways, particularly combinations of pathway aberrations, 
contribute to the development of different subtypes of cancers. Such an understanding will 
further guide the development of distinct treatment strategies for tumors with different disease 
mechanisms. A better understanding of what treatment methods work for different cancer 
patients would allow an individual to be given treatments that have the best chances for success 
[70, 71]. This would decrease the amount of time spent ruling out ineffective treatments and 
limit the drugs and potential side effects that a patient is exposed to. Another approach to using 
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this understanding to improve cancer treatment is through drug development. An aim in cancer 
treatment is to identify drugs that can target cancer cells while limiting the impact on normal 
tissues. Cancer drivers and disease mechanisms that are identified are potential targets for drug 
development. Alternatively, this information can be used for drug repurposing, if an existing 
drug is already known to affect these drug targets. 
The overarching goal of this study is to investigate the distinct disease mechanisms of 
cancers by mining the combinatorial patterns of pathway aberrations, which in turn can be 
inferred by mining the combinatorial patterns of SGAs perturbing the pathways. However, this 
task is challenging because a pathway can be perturbed by distinct SGAs that affect different 
member proteins of the pathway, which leads to the well-known phenomenon that few tumors 
share common SGAs even though a common set of pathways are perturbed. The key task that 
needs addressing is to identify the common pathways that are affected by distinct SGAs in 
different tumors.  By starting with the SGAs in tumors, it is necessary to determine the pathways 
that they lie on, and thus the functions they are involved in. Since gene names themselves do not 
convey the function of a gene, thereby being insufficient for inferring the functional similarity of 
distinct genes, an alternative representation of genes is needed to assess the functional similarity 
of genes with distinct names. For example, in a representation we call semantic embedding, a 
gene can be represented by a set of words from literature that describe the function of the gene.  
If a significant number of words are shared in the two word sets describing two distinct genes, 
the functions of the two genes are likely to be similar. Different sets of words are used to 
describe different gene functions, and each of these word sets is associated with a topic. Once 
tumors are composed of these representations, we would need to detect the patterns in their 
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altered pathways through the patterns in the words. Such a task can be accomplished through the 
application of topic modeling. 
1.2 TOPIC MODELING 
In text mining, a common method of capturing the statistical structure of a corpus of texts is to 
capture the tendency of certain words to co-occur when a semantic topic is discussed.  By 
capturing such structures, one can represent a text as a mixture of words from such topics, which 
serve as a more concise and abstract representation of documents in the corpus than individual 
words. The goal of identifying representative features, like topics, for samples has been 
approached in many different ways. Two of the methods that involve matrix factorization are 
singular value decomposition (SVD) [72] and nonnegative matrix factorization (NMF) [73], 
which are similar to principal component analysis. When given a corpus represented as a 
document-by-word matrix, these methods factorize the matrix into a word-by-feature matrix and 
a feature-by-document matrix. The word-by-feature matrix identifies what words are associated 
with a given feature, while the feature-by-document matrix identifies what features are 
associated with a given document. Both SVD and NMF are methods to perform latent semantic 
indexing that also results in dimensionality reduction. One of the limitations of SVD is that it 
requires the discovered features to be orthogonal. This means that the features must be 
independent of each other. NMF does not have this restriction, allowing dependencies to exist 
between features. NMF also limits the matrixes from having negative values, which SVD 
permits. By allowing feature matrices to only have non-negative values means that the resulting 
semantic features have greater interpretability. However, both of these methods are not 
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probabilistic, and so they can’t capture the probability that a feature is associated with a 
document in the corpus.  
1.2.1 Probabilistic Topic Models 
Topic models were originally developed for use in text mining, and are capable of learning the 
major topics associated with a document based on its words. In this setting, a topic is represented 
as a probabilistic distribution over a space of words, which capture the tendency of words to co-
occur when discussing a specific semantic topic.  The idea is that a document, such as an article 
or a paper, is about more than one topic. When a topic is discussed, words related to that topic 
would occur more frequently. For example, there is a corpus of documents related to cancer. One 
of the topics in the corpus is related to cell death and has words such as “cell”, “death”, and 
“apoptosis” associated with it. When a document in this corpus has the topic “cell death” then 
these associated words would occur more frequently. The distributions of these topics also vary 
by document, and so two documents with different distributions of the same topics would also 
have different distributions of words. Thus, by examining a corpus of documents, it would be 
possible to use the words to learn what the topics in the corpus are, and what distribution of 
topics each document contains. Continuing from the example above, another topic in the corpus 
is related to cancer treatment. One document in the corpus can be focused on research of a 
pathway that results in cell death, and also covers it potential application in cancer treatment. A 
second document can be focused on different treatments of cancer, and also mentions the 
resulting death of cancer cells. As such, even though both documents have the same topic 
associations, they have different distributions of the two topics, which is reflected by the 
different distributions of associated words. 
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One of the earlier topic models is probabilistic latent semantic indexing (PLSI) [74]. It is 
a generative model that represents the probability of topic and word co-occurrences as mixtures 
of conditionally independent multinomial distributions. In this representation, the words in a 
document are assumed to be generated independently, which means that the ordering of the 
words does not matter. As such, each document is treated as a bag-of-words. Another assumption 
made is that the words in a document are conditionally independent given the associated topics. 
PLSI allows a mixture of topics to be assigned to a single document, where the topics are 
characterized as distributions of words, and is able to assign topic labels to previously unseen 
documents after the model is already learned. However, this model does not make assumptions 
about how to assign topic weights to documents, and so only learns topic distributions for the 
documents in the training set. This makes it difficult to generalize the model to new documents 
added to a corpus. 
The most commonly used topic model is latent Dirichlet allocation (LDA), which is also 
the basis for many other topic models [75]. LDA is a Bayesian model of a collection of 
documents that is an extension of PLSI. Therefore, it is based on the same concepts as PLSI, and 
represents topics and documents in the same manner. In addition to the assumptions made in 
PLSI, LDA assumes that the topic distribution has a Dirichlet prior. For each document in a 
corpus, LDA sets the prior for the words to be a Poisson distribution, and the topic mixture 
weights to be a Dirichlet distribution. In other words, LDA is able to regenerate a document in 




In this notation, 𝑁 is the number of words (𝑤) in the document; 𝑧 is a topic; and 𝛩, 𝛼, and 𝛽 are 
model parameters. The addition of this Dirichlet prior allows LDA to generate topic probabilities 
for new documents. This means that LDA is a generative model that overcomes the difficulty of 
generalization to new documents. Yet, like PLSI, the topics learned by LDA have a flat structure 
to them, which means that the presence of a topic in a document is independent of the other 
topics that may exist in the document (Figure 1-1A). However, this independence isn’t true in the 
altered signaling pathways of cancer. Thus, a model that is capable of capturing the relationship 
between topics is necessary.  
While unable to identify topic relationships, one type of model that has been used to 
capture the relationship between documents is the relational topic model. A relational topic 
model takes as input documents and their associated document network, where a document is 
linked through citations or other means. Topics and topic assignments are then learned and used 
to generate a network structure, with the aim of recreating both the documents and the document 
network. By requiring the topics to be used to recreate the document network, the learned topics 
would be able to explain the original network structure. In comparison, models that do not 
require this coupling between the topic and the network may result in two subsets of topics, one 
that is used to explain the networks and the other used to explain the words. As a result, the 
1. Choose 𝑁 ~ Poisson(𝜆) 
2. Choose 𝛩 ~ Dirichlet(𝛼) 
3. For each of the 𝑁 words 𝑤𝑛: 
a. Choose a topic 𝑧𝑛 ~ Multinomial(𝛩) 
b. Choose a word 𝑤𝑛 from 𝑝(𝑤𝑛|𝑧𝑛, 𝛽), a multinomial probability 
conditioned on the topic 𝑧𝑛. 
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topics would not be useful for predicting the relationship between edges and words. However, 
relational topic models are still unable to capture relationships between topics.  
In reality, the topics that occur in a document are not independent as assumed in LDA. 
Instead, they have hierarchical relationships where topics that are more general and appear more 
frequently in a corpus are higher in the hierarchy, and topics that are more specific and appear 
less frequently are deeper in the hierarchy (Figure 1-1B). For example, with the document 
focused on a pathway that results in cell death, the topics related to this document can include the 
most general topic of biology, followed by increasingly more specific topics of cellular 
processes, cell death, and apoptosis. In this corpus there would be more documents that contain 
the general topic of biology than the more specific topics. Extensions of LDA have been 
developed that are capable of learning these hierarchical relationships between topics [76-79]. 
These models generate a structured prior on topics contained in a corpus of documents, which 
results in topics that have a hierarchical structure. This structure matches our interests because, 
as mentioned earlier, different alterations have different degrees of specificity. Therefore, the 
alterations that occur in many different cancer types would be like the topic “biology” from the 
example earlier, while the alterations limited to specific cancer types would be like the topic 
“apoptosis”. The nested hierarchical Dirichlet process (nHDP) allows a document to access the 
entire tree and be labeled with topics that lie along different branches of the tree [77]. This gives 
the model greater flexibility, and does not force documents to be associated with unrelated 
topics. We hypothesize that establishing a framework that uses the nHDP would allow us to 








Figure 1-1. Example topic structures for the latent Dirichlet allocation and nested hierarchical 
Dirichlet process. Examples of two possible topic structures that can be learned through topic modeling using A) 
latent Dirichlet allocation or B) nested hierarchical Dirichlet process. Circles represent topics and lines represent 
relationships between topics. Topics higher in the hierarchical tree are more general, and become more specific as 
they go deeper into the tree. 
 
 
To summarize, while PLSI makes it possible to generate probabilistic mixtures of topics 
for documents, its limited assumptions makes the model unable to generalize to documents that it 
is not trained on. LDA overcomes this by adding an assumption about the topic distribution for a 
document. Both of these models generate topics that are independent of each other, which may 
not be true in all datasets. Hierarchical topic models overcome this limitation, and nHDP has an 
increased flexibility in the generated topic tree structure over other hierarchical models.  
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1.2.2 Application to Biomedicine 
Due to its capabilities, topic modeling has been applied to some areas of biomedical research. 
Since these algorithms were first developed with textual data in mind, it has been used to process 
biomedical text. This can include processing biomedical literature for different purposes, such as 
identifying the important concepts in the document themselves [80] or their associated genes 
[81]. Analysis of gene expression data is another area where topic models are more frequently 
used. The goal can be to simply classify or cluster samples based on changes in gene expression 
under different conditions [82-84]. Lee et al. used toxicogenomic gene expression data to try to 
find common functional features affected by different drugs or tested using different conditions 
[83]. Similarly, this has also been used to analyze high content screening data generated from 
different drugs [85]. In these situations, where actual words and documents do not exist, 
adaptations are used. Oftentimes each sample is treated as a document, each gene or endpoint as 
a word, and the measurement associated with the gene or endpoint as the word count [82-85]. 
Other less common applications also exist, such as applying topic models to study the functional 
core in taxonomy [86]. In most cases, LDA was the topic model used to analyze the data [80-83, 
85, 86]. However, the hierarchical Dirichlet process model has been applied to gene expression 
clustering, because the structure of the model better captures the hierarchical structure of 
biological functions [84]. 
In a prior instance, a relational topic model was applied with the goal of identifying 
genomic features that can explain the phenotypic similarities of different cancer tumors. 
Working with Glioblastoma Multiforme tumors, Cho and Przytycka used gene expression data as 
a representation of disease phenotype to create a phenotype similarity network [87]. Mutations, 
gene copy number variations, and microRNA dysregulation were used as genomic features, 
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where a “word” variable was created for each gene and each variation observed for the gene. 
These word variables were then used to generate the tumor documents. The topics and network 
generated were used to identify the genomic features that could explain the phenotypic 
similarities [87]. However, the model used is unable to capture hierarchical structure of 
functions. Given the nature of the representation of genes, which does not capture their function, 
it is difficult to identify genes with similar functions that can be shared across different subtypes. 
1.3 FUNCTIONAL SIMILARITY OF GENES 
The goal of using an alternative representation of genes is to be able to assess their functional 
coherence or similarity. This is due to the fact that gene names themselves do not provide much 
information. Thus, additional information about gene function is necessary in order to be able to 
identify similar genes. As such, a computational algorithm would not be able to find functional 
similarities between two different genes if we directly used gene names as words. For example, 
if we just had the words PI3K and AKT, they seem independent. However, once we represent the 
fact that they are both part of a signaling pathway involved in apoptosis their functional 
similarity is apparent. Through this idea of using additional information, different measures of 
functional coherence have been developed. Two of the larger types of methods are by using gene 
annotations or by using associated literature. 
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1.3.1 Using gene annotations to identify functionally similar genes 
Databases containing controlled vocabularies of terms, such as the Gene Ontology (GO) [88], 
were created in order to have a unified language when annotating genes. This means that gene 
annotations related to gene function can be a resource for determining functional coherence. The 
most frequently used method is to determine if a specific annotation term is enriched in a list of 
genes. Thus algorithms often are based on statistical tests of over-representation such as the 
hypergeometric distribution [89] or Fisher’s exact test [90]. Gene annotations can also be used to 
generate annotation profiles, which can then be used to measure the similarity between genes. 
For example, a kappa statistic co-occurrence score can be measured between genes based on 
their annotations [91]. These score distributions could be used to group similar genes [91]. 
These annotation-based methods can also be developed further by including methods 
such as multiple hypothesis correction [89], or incorporating GO structure into the analysis [90]. 
The GO has a hierarchical structure where parent nodes encompass all the information held 
within children nodes. Since genes are only annotated with the most specific term applicable, 
ignoring this structure would make it more difficult to accurately measure the functional 
similarity of genes. One method of incorporating the GO structure is to adjust the weight of the 
gene annotations used when calculating enrichment scores [90]. However, even with these 
improvements, annotation based methods are often restricted to analysis of gene lists. They are 
also limited by the amount, and accuracy, of gene annotations and annotation terms available.  
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1.3.2 Using literature to identify functionally similar genes 
Methods that directly use the literature associated with genes are able to bypass the need for gene 
annotations. This requires the genes to be represented in a way that captures the information 
contained in the literature. The most frequently used method to do this is through a bag-of-
words, vector space representation [81, 92-96]. Such a representation ignores the order that terms 
appear in a document, and just captures its presence in a document. These vector space 
representations can then be used to identify the important semantic features of genes. Methods 
using associated literature would also be limited by the amount of literature available. However, 
they do avoid the complications involved with the extra annotation step. 
1.3.2.1 Representing genes in the vector space  
The main variations in vector space representations lies in what method is used to track, 
or index, the importance of a term in a document. The simplest indexing method is binary, which 
assigns a 1 if the term occurs in a document and a 0 if it does not [93]. Term frequency can be 
directly used as an indexing measure to capture importance based on the number of times a term 
occurs in a document [93]. However, if a term appears in many documents in a corpus, then its 
presence in an individual document would not convey as much information. As such, most 
methods use term frequency-inverse document frequency (tf-idf) [92, 93, 96], which normalizes 
term frequency based on the number of documents the term appears in. Example vectors using 
these three indexing methods can be seen in Table 1-1. Other indexing methods that correct 
values based on document distributions are also available [95], as well as those that are based on 
if a document refers to other documents [93]. 
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Table 1-1. Example vectors using three different indexing methods 
Binary 
 
Term Frequency  tf-idf 
activ 1  activ 79351.05  activ 255.15 
apoptosi 1  apoptosi 41463.75  apoptosi 307.14 
associ 1  associ 69460.42  associ 200.17 
cancer 1  cancer 104378.64  cancer 407.73 
cell 1  cell 150998.09  cell 371.00 
codon 1  codon 10760.11  codon 283.16 
dna 1  dna 37610.01  dna 287.10 
express 1  express 92302.17  express 225.13 
mdm2 1  mdm2 8741.60  mdm2 364.23 
mutat 1  mutat 90268.99  mutat 423.80 
neurogenet 0  neurogenet 0  neurogenet 0 
p53 1  p53 310367.08  p53 3979.07 
protein 1  protein 54966.58  protein 116.70 
regul 1  regul 56595.32  regul 158.98 
tp53 1  tp53 33462.43  tp53 984.19 
tumor 1  tumor 63526.75  tumor 319.23 
vasodil 0  vasodil 0  vasodil 0 
 
1.3.2.2 Identifying semantic features associated with genes 
Different methods have been used to identify the important semantic features associated 
with a specific gene out of the entire vocabulary space, which is generally at least a few thousand 
terms. Methods that have been used to identify these features include latent semantic indexing 
[95], non-negative matrix factorization [92, 96], and latent Dirichlet allocation [81]. All of these 
methods result in a gene-to-feature adjacency matrix. These adjacency matrices can then be used 
in a number of ways, such as clustering genes based on their feature similarities to identify 
related gene sets [92, 95, 96], or to rank genes based on given queries [95]. The matrices have 
also been used to create bipartite graphs, and the functional coherence of genes was then 
measured based on graph connectivity [81]. The generated features have to be further analyzed 
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in order to determine what they represent, and identify the meanings of the featured shared 
between gene sets.  
1.3.3 Evaluation 
The evaluation methods of functional coherence algorithms have mainly focused on three 
different aspects: the accuracy of the algorithms, the quality of the generated gene clusters, and 
the stability of the algorithms. Measuring the accuracy of an algorithm involves determining if it 
is capable of correctly determining the functional coherence of genes. Since clustering is often 
used to identify clusters of functionally coherent genes, some methods have evaluated the 
coherence of the generated clusters. The stability of the algorithms is measured to determine 
their performance under different situations. 
1.3.3.1 Algorithm Accuracy 
Two different evaluation methods have been used to determine the accuracy of 
algorithms: evaluation through the use of datasets or expert evaluation. In order to correctly 
measure accuracy, the true functions of the genes in a dataset are necessary. Therefore, yeast 
datasets are frequently used, since they are well-studied and the gene functions are better 
understood. The results generated using yeast datasets are qualitatively analyzed to determine if 
they are reasonable and the gene clusters correspond with established functions [89, 91-93]. In 
order to ensure that the results obtained are based on the data, they can be compared with random 
datasets generated by shuffling the data matrix [92]. Datasets can also be generated in order to 
have a gold standard for evaluation. This can be done by selecting genes with known functions 
[95] or just artificially generating data [90]. Knowing the genes’ function makes it possible to 
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calculate the precision and recall for an algorithm that can rank functionally related genes based 
on a query [95]. When evaluating if an algorithm can correctly identify functionally enriched 
terms, artificially enriching the terms makes it possible to evaluate and compare the performance 
of different algorithms [90]. Some authors have run datasets without well-established gene 
functions, which can be used for qualitative evaluations of the algorithms [81, 91, 92]. Expert 
evaluation is a potential method for qualitative evaluation. Chagoyen et al. used it to determine if 
the semantic features generated were coherent to a specific function [92]. However, individuals 
may differ in opinion, and multiple experts would be needed to be able to get a more accurate 
measure. 
1.3.3.2 Clustering Performance 
In order to evaluate the performance of clustering to create cohesive gene clusters, a 
couple of different metrics are available. Two of the more traditional measures are the Rand 
index [97] and the silhouette score [98]. The Rand index is used to measure the similarity of two 
data clusters, and so it can be used to compare a generated cluster with a set of genes treated as 
the ground truth [93]. In order to correct for random partitions, an adjusted Rand index was 
developed which uses a hypergeometric distribution as a model for randomness [99]. If there is 
no gold standard for comparison, the silhouette score can be used. This score measures how well 
each data point lies within its cluster, and so it can also be used to determine appropriate cluster 
sizes for a dataset. One other method that has been used is to treat the clusters as class labels, and 
to calculate a misclassification score for the resulting clusters [93]. Similar to the Rand index, a 
gold standard is needed in order to accurately calculate the misclassification scores. 
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1.3.3.3 Algorithm Stability 
Measuring the stability of an algorithm means determining how sensitive it is to the data 
and other factors. Highly sensitive algorithms are less reliable because they would give very 
different results under slightly different conditions. When an algorithm contains stochastic or 
adjustable components, such as initializations, repeated executions while randomizing the 
components can be performed. This evaluation method can be used to determine if the results of 
the algorithm are produced by chance [96]. However, this does not reveal how sensitive an 
algorithm is to the input data. One method of determining this is to add noise to the data, and 
evaluating if the algorithm is still able to perform under these conditions [92]. Another method of 
reducing the signal-to-noise ratio is to reduce the amount of signal available, such as by 
decreasing the threshold for differentially expressed genes and evaluating the stability of the 
results with the smaller gene sets of interest [90]. Only a combination of tests would be able to 
determine the stability of algorithms given different input and variables. A gold standard for data 
used for these tests would be needed in order to properly evaluate the results, which is difficult 
given the limitations of current biological knowledge. 
1.4 RESEARCH OVERVIEW 
It is important to identify the disease mechanisms related to cancer in order to have a 
better understanding of its development. Being able to understand the combinations of perturbed 
pathways in cancer may also lead to better treatment of the disease. Thus the identification and 
incorporation of driver genes to identifying the perturbed pathways is important. Since topic 
modeling can be used to identify common themes across different documents, it can potentially 
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be used to identify perturbed pathways shared across different tumors. To do this, it is necessary 
to use a representation of genes in order to be able to identify genes that are functionally similar 
and part of the signaling pathway.  
The aim of the research is to identify patterns in the signaling pathways perturbed in 
cancer. We used two types of alternative representations of genes, semantic and biological, to 
capture the perturbed pathways in individual tumors. Driver genes were predicted for each 
cancer tumor using somatic genomic alteration and gene expression data. Topic modeling was 
then used to identify the pathway perturbations that occur and are shared in different tumors. The 
methodology to do this was developed and applied to cancer data, and shows the potential to 




2.0 REVEALING COMMON DISEASE MECHANISMS SHARED BY CANCERS OF 
DIFFERENT TISSUES OF ORIGIN THROUGH SEMANTIC REPRESENTATION OF 
GENOMIC ALTERATIONS AND TOPIC MODELING 
2.1 INTRODUCTION 
Cancer is a complex disease involving multiple hallmark processes [7, 10], and aberrations in 
these processes are caused by somatic genomic alterations (SGAs) that perturb pathways 
regulating these processes. Different combinations of pathways lead to heterogeneous oncogenic 
behaviors of cancer cells, which impact patient outcomes and response to treatment. 
Identification of combinatorial patterns of pathway perturbations can reveal common disease 
mechanisms shared by a tumor subtype and such information can guide targeted therapy. 
Transcriptomic data have been widely used to reveal different cancer subtypes among 
tumors of the same tissue of origin, and such studies have identified many clinically relevant 
subtypes, which have significant prognostic value [25-28, 67, 100-103]. However, 
transcriptomics-based subtyping does not provide insight into the disease mechanisms 
underlying each subtype, that is, transcriptomics-based subtyping does not reveal the causative 
pathways underlying the development of subtypes.  As such, such subtyping does not provide 
guidance for targeted therapy. Another limitation of transcriptomics-based subtyping is that 
tissue-specific gene expression prevents discovery of transcriptomic patterns across cancer types. 
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Recent pan-cancer studies found that tumors are invariably clustered according to tissue of 
origins when using features that are related to transcriptomics [35, 38]. Therefore, studying 
common disease mechanism of cancers should be addressed from new perspectives. 
In order to gain a better insight into cancer disease mechanisms, an alternative approach 
is to study SGAs that perturb signaling pathways with the goal of identifying which perturbed 
pathways underlie each of the subtypes. It can be hypothesized that each cancer subtype is likely 
driven by a specific combination of perturbed pathways, and identification of such common 
disease mechanisms would provide guidance for targeted therapy.   
However, the direct use of SGA data to identify these signaling pathways is challenging. 
This is because pathways are composed of multiple genes, and in different tumors the same 
pathway can be perturbed by distinct SGAs affecting different members of the pathway. As such, 
two tumors sharing common pathway perturbations may exhibit totally different sets of SGAs, 
making it difficult to detect similarities between tumors. Thus individual tumors may present 
itself with different genomic alterations, while undergoing the same pathway perturbations [45]. 
This effect is amplified by the fact that multiple pathways need to be perturbed for cancer to 





Figure 2-1. Conceptual overview of research. A) Somatic mutation, copy number alteration, and gene 
expression data for each tumor was collected. B) GeneRIF and gene summaries associated with genes were 
collected. C) The semantic data associated with each gene was processed to create a word vector representation 
(note the differences in the word frequency profile for different genes). D) A document representation for each 
tumor was created by combining the word vectors of each SGA associated with the tumor. E) The document 
representations were used as input for a hierarchical topic model, which identified topics associated with each 













































































































































































































































































































In order to tackle this problem, we have developed a novel semantic representation of 
tumors that captures the similarity of functions of distinct genes. This representation would help 
us identify functionally related genes whose alterations result in similar changes in signaling 
pathways. We also chose to use topic modeling to identify patterns in these altered signaling 
pathways based on the semantic representations. The tumors were clustered based on these 
patterns, and a survival analysis was performed on the results. The conceptual overview of our 
research is shown in Figure 2-1. 
2.2 METHODS 
2.2.1 Data Processing 
2.2.1.1 Cancer Genomic Data 
Cancer somatic mutation data was downloaded (July, 2013) from The Cancer Genome 
Atlas (TCGA) and copy number variation and gene expression data was downloaded from The 
UCSC Cancer Genomics Browser [104, 105]. Data from five different cancer types was used: 
breast invasive carcinoma (BRCA), head and neck squamous cell carcinoma (HNSC), lung 
adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and ovarian serous 
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cystadenocarcinoma (OV), where the LUAD and LUSC data was combined into one large lung 
cancer (LUNG) dataset for processing. 
2.2.1.1.1 Somatic Mutations 
PolyPhen-2 was used to determine which somatic mutations for each cancer sample had a 
potential effect on protein function, where each cancer sample was a different cancer tumor 
[106]. We considered a mutation event that was labeled either “possibly damaging” or “probably 
damaging” to be a functional mutation. Since the tool can only analyze single nucleotide 
polymorphisms, it was used to analyze all the missense mutations. The frame shift, nonsense, 
splice site, and multiple nucleotide mutations were considered functional mutations, because of 
their tendency to have a larger impact on protein function. This analysis was used to determine 
the functionally mutated genes for each cancer sample for each cancer type.  
2.2.1.1.2 Copy Number Variation 
We only considered the genes whose copy number variations resulted in an altered gene 
expression. In order to determine if the expression of a sample was altered, we first calculated 
the mean and variance of the samples with no copy number variation. These values were then 
used to calculate the probability of a gene to be differentially expressed using a one-tailed test on 
a normal distribution. If the probability fell below the threshold, then we considered the 
expression to be altered and kept the sample for further analysis. In this analysis, we only 
considered the instances where the gene was marked as +/-2 in copy number, and a probability 
threshold of 0.01 was used. For each cancer type, we utilized the gene expression data that 
contained the most samples. 
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2.2.1.1.3 Combined Data 
The somatic mutation and copy number variation data were combined in order to get a 
more comprehensive view of the genes that are altered in each tumor. Thus a combined sample 
to SGA matrix was created. This matrix contains, for each cancer sample, each gene that was 
either functionally mutated or had a copy number variation that resulted in an altered gene 
expression. In order to reduce the sizes of the datasets and decrease the chances of including 
passenger mutations, a frequency threshold was set and any SGA that occurred less frequently 
than that threshold was eliminated. The cancer types were combined and a threshold of 20 was 
used. This threshold was selected because we had a total of 2,396 samples and this value is close 
to 0.01% of the total samples. 
2.2.2 Representation of Genes and Tumors 
2.2.2.1 Semantic Representation of Genes 
Semantic data was obtained from three different sources, which could be used as 
independent data sources: PubMed articles, GeneRIFs, and gene summaries. PubMed articles 
were downloaded from PubMed on April 10, 2013. The rest of the data was downloaded from 
NCBI Gene: gene to article associations was downloaded on April 9, 2013, and both GeneRIFs 
and gene summaries were downloaded on September 16, 2013. This text was preprocessed by 
removing stop words, tokenization, and Porter stemming [107].  
2.2.2.1.1 Tf-Idf Calculation 
We calculated the term frequency-inverse document frequency (tf-idf) of each word to 
determine which words contained information pertinent to a gene. To do so, we tried two 
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different methods of generating the corpus used when calculating tf-idf score: 1) treating the 
gene list for each cancer type as a separate corpus whose tf-idf scores were generated separately, 
and 2) treating the entire list of genes as one large corpus. For each corpus generated, each gene 
represented a document. The term frequency (tf) and document frequency (df) were calculated 
for each word in each gene, with the term frequency being the number of times the word is 
associated with the sample, and the document frequency being the number of samples the word 
is associated with. Using these values, we then calculated the tf-idf for a specific word with: 




where w represents the word, d is the cancer sample (or document), and D is the entire corpus. 
Thus |𝐷| represents the total number of tumors. The cumulative tf-idf for each word was 
calculated by summing the tf-idf score across all documents. 
2.2.2.2 Semantic Representation of Tumors 
2.2.2.2.1 Word Vector Creation 
Word vectors containing relevant words and their term frequencies are needed for the 
topic modelling process. The calculated tf-idf and cumulative tf-idf scores were used to limit the 
vocabulary size across the entire dataset as well as for each gene. Only the 20,000 words with the 
highest cumulative tf-idf scores were included in the vocabulary. A word vector was then created 
for each gene by going through its list of 200 words with the highest tf-idf scores and including 
only the ones that occur in the vocabulary. We also tested the idea of altering some of the word 
vectors created by altering the tf-idf score for each gene’s gene name and aliases. These scores 
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were altered by setting the tf-idf score for each gene’s gene name and aliases equal to the highest 
tf-idf score associated with that gene.  
In order to obtain the word vector associated with a cancer sample, we utilized only the 
genes altered in that sample. For each sample, we combined the word vectors for all of the genes 
altered in the cancer sample. The values for each word in a sample word vector were set by 
summing the tf-idf scores for the word across all genes with word vectors containing the word. 
2.2.3 Topic Modeling 
2.2.3.1 Nested Hierarchical Dirichlet Process 
The nested hierarchical Dirichlet process (nHDP) is a hierarchical topic model [108], 
which uses Bayesian nonparametric prior to model the covariance of topics in a training corpus. 
nHDP represents the relations among topics using a tree, in which a node represents a topic and a 
path in a tree indicates that the topics on the path have a high tendency to co-occur in documents. 
When modeling the topics present in a text document, nHDP allows each document to access the 
entire tree [108] (considering all possible topics) and places a high probability on multiple paths. 
The nHDP algorithm was run on the word vectors created using the cancer data, with each tumor 
treated as a separate document. The returned results contain a topic matrix containing the words 
associated with each topic, and a document-topic distribution matrix containing the number of 
words from each tumor (document) that are associated with each topic. We used the parameter 
value 𝛽0 = 0.01, and we define the maximal level of the tree to be 3 and initialized the tree with 
the parameters 10, 5, and 3. The nHDP algorithm was run 10 times to generate 10 different topic 
models for each dataset. 
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2.2.3.1.1 Topic Model Selection 
The model that had the highest cumulative document likelihood was selected as the best-
fitting topic model. To calculate the cumulative document likelihood for a specific model, we 
used its outputs to obtain two matrices: 1) the matrix containing the number of words from each 
document associated with each topic and 2) the matrix containing the probability of each word 
occurring in each topic. We first calculated the probability of each topic (t) being associated with 
each document (d) by dividing the number of words in d that is associated with t by the total 
number of words in d. The likelihood for d is calculated by first calculating the word probability 
for each word (w) by summing the probability of w given t times the probability of t given d. The 
document log likelihood is then calculated by summing up the log of the probability of each 
word. 
 




Matrix containing number of words from each document associated with each topic 
Matrix containing probability of each word occurring in each topic 
 
Initialize:  
cumulativeDocProb - a variable to store the cumulative document log likelihood 
 
cumulativeDocProb = 0 
foreach document (d) 
docProb = 0 
Calculate probability of each topic being associated with d  
foreach word (w) in d 
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wordProb = 0 
foreach topic (t) 
wordProb = wordProb + p(w|t) * p(t|d) 
docProb = docProb + log(wordProb) 
cumulativeDocProb = cumulativeDocProb + docProb 
 
2.2.4 Analysis 
2.2.4.1 Calculating Topic to Gene Associations 
Since the topics in our setting reflect the functions that are repeatedly perturbed by SGAs 
among all tumors, it would be interesting to know which SGAs are associated with each 
functional theme. However, the nHDP model only captures the association of words with topics. 
Further calculations were needed to determine the SGAs associated with each topic. Utilizing the 
topic to document association and topic to word association matrices generated by the topic 
model, we calculated the topic to gene associations for each topic (t). The topic to document 
association matrix contains the number of words from each document that is associated with 
each topic; this was used to calculate the probability of each topic being associated a document 
by dividing the number of words associated with a topic by the total number of words in the 
document. The strength of association to each gene for topic t was then calculated by cycling 
through each document (d). We then further cycled through each word (w) associated with each 
gene (g) that is in d. The strength of association of g was then calculated by summing the count 
for w times the probability of t given d and the probability of w given t. 







Matrix containing probability of each word occurring in each topic  
Word vector representation of each gene 
Matrix containing number of words from each document associated with each topic 
 
Initialize:  
topicGeneMatrix - an empty topic by gene matrix 
 
foreach topic (t) 
foreach document (d) 
Calculate probability of t being associated with d 
foreach gene (g) in d 
foreach word (w) in g’s word vector 
topicGeneMatrix[t][g] = topicGeneMatrix[t][g] + w count in g * p(t|d) * 
p(w|t) 
 
2.2.4.2 Clustering Tumors 
In order to determine if the topics obtained through the nHDP learned additional 
relationship information from the data, we performed consensus clustering to cluster the tumors 
using either the altered genes or the word count per topic association as features. We used 
partitioning around medoids (PAM) as the clustering method. The algorithm was run for cluster 
sizes 4-6 using 10 repetitions when clustering based on the altered genes; it was run for cluster 
sizes 4-10 using 20 repetitions when clustering based on the word count per topic association. 
Consensus clustering was performed using the clusterCons package version 1.0 in R [109]. 
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2.2.4.3 Visualization of Tumor Clusters 
In addition to consensus clustering, we also chose to visualize the tumors (documents) in 
order to see how clearly our topic model was able to separate the different samples. The t-
Distributed Stochastic Neighbor Embedding (t-SNE) technique of dimensionality reduction was 
used to plot the points in a two-dimensional space [110]. This allowed us to directly use the word 
counts per topic for each tumors as input for plotting, after first removing the topics that do not 
have any associated samples. We used the Matlab implementation downloaded from 
http://homepage.tudelft.nl/19j49/t-SNE.html.  
2.2.4.4 Calculating Cluster to Topic Associations 
The proportion of samples (documents) in a cluster associated with each topic was 
calculated to see how topic associations vary between different clusters. In order to determine 
which documents are associated with each topic, the proportion of words from each document 
associated with each topic was calculated. Any topic that was associated with at least 0.01 of the 
words in a document was considered to be associated with the document. This threshold was 
used to remove associations that are the result of noise. We then obtained the proportion of 
documents in each cluster that are associated with each topic. 




topicClusterMatrix - an empty topic by cluster matrix 
 
foreach cluster (c) 
Get all documents in cluster 
foreach topic (t) 
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Counter number of times t is associated with documents in c 
foreach cluster (c) 
Divide counts by the number of documents associated with c 
 
2.2.4.5 Survival Analysis 
In order to determine if there was a biological impact in subtyping the tumors based on 
clustering, we chose to perform a survival analysis. Kaplan-Meier survival analysis was done on 
the tumors with the same cancer type. These samples were separated into subsets based on the 
clustering results obtained previously. Survival data for the tumors were obtained on May 2, 
2016 from the clinical data available on TCGA [25]. The analysis was performed twice for each 
cancer type: once using all tumors, and once after excluding all clusters that contained less than 
25 samples. We used the survival package version 2.38.3 in R to conduct the analysis [111, 112]. 
2.3 RESULTS 
2.3.1 Cancer Data 
The combined somatic mutation and copy number variation data resulted in datasets of the 
following sizes (Table 2-1): BRCA with 779 samples and 15,517 genes; HNSC with 324 
samples and 14,548 genes; LUAD with 398 samples and 11,851 genes; LUSC with 331 samples 
and 10,874 genes; and OV with 562 samples and 10,235 genes. This resulted in a dataset with 
2,396 samples and 20,760 genes after combining all four cancer datasets, and 2,396 samples with 
2,733 unique genes after applying a threshold. 
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Table 2-1. Number of tumors and number of genes for each cancer type 
Cancer Type Number of Samples Number of Genes 
BRCA 779 15,517 
HNSC 324 14,548 
LUAD 398 11,851 
LUSC 331 10,874 
OV 562 10,235 
Combined 2,396 20,760 
Thresholded 2,396 2,733 
 
2.3.2 Semantic Data  
Word vectors were created using the different semantic data sources. Four different 
combinations of data were used to generate word vectors: 1) PubMed articles, 2) GeneRIFs, 3) 
gene summaries, and 4) GeneRifs and gene summaries combined. The vocabulary sizes of these 
resulting word vectors were: 357,577 word for PubMed articles; 54,755 words for GeneRIFs; 
7,933 words for gene summaries; and 57,035 words for GeneRifs and gene summaries 
combined. 
2.3.2.1 Construction of Gene Word Vectors  
We created a word vector for each gene using the different semantic data sources. Since 
the words used to represent a gene are related to the gene’s function, the word vectors highlight 
the similarities and differences between two genes. A subset of words with their tf-idf scores 
from the word vectors of three genes are given as examples in Table 2-2. Both TP53 and MDM2 
are known cancer genes. TP53 is a tumor suppressor that is involved in apoptosis and DNA 
repair, and MDM2 is a proto-oncogene that inhibits TP53. On the other hand, the TTN gene 
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encodes for a protein that is important in muscles. The shared words in the word vectors for 
TP53 and MDM2 reflects their similarity, especially when compared against the word vector for 
TTN. 
The number of words in a gene word vector provides information on if there is enough 
data to fully represent the altered gene. As such, the distribution of the length of the gene word 
vectors informs us about how well the genes are represented using the semantic data. The main 
factor that impacts the gene word vector length is the data source, because the variations applied 
to the word vectors are all based off of the tf-idf calculated from these datasets. The resulting 
distributions tell us that no single data source is able to fully represent all of the 2,726 altered 
genes (S Figure 1). This is especially true for the gene vectors generated using only gene 
summary data, as around one third of the word vectors do not even have any words. It is only 
after combining the GeneRIF and gene summary data that the number of genes without any 
words falls below 400 and a larger portion of genes are represented by a full 200 words. When 
using PubMed articles, the number of genes without any words associated is much smaller, but 
we also have fewer genes that are represented by a full 200 words. 
Another factor that needs to be considered about the representations is the quality of the 
information of the data sources used to create the word vectors. The GeneRIFs and gene 
summaries provide direct information regarding the gene and its function. While this means that 
such information is not provided for all genes, this does limit the amount of noise. On the other 
hand, Pubmed articles cover a greater number of genes. However, there is a lot more noise 




Table 2-2. Subset of words from word vectors for three different genes created using GeneRIFs and gene summaries 
with altered tf-idf scores for gene names. 
TP53  MDM2  TTN 
Word Tf-Idf  Word Tf-Idf  Word Tf-Idf 
p53 4084  hdm2 629  ttn 88 
tp53 4084  mdm2 629  titin 88 
cell 1443  hdmx 629  domain 31 
cancer 890  p53 363  pevk 18 
express 887  cell 150  region 17 
mutat 788  cancer 136  protein 16 
activ 683  associ 117  muscl 15 
gene 615  regul 113  mutat 15 
associ 614  activ 97  structur 14 
protein 602  express 95  elast 12 
tumor 563  snp309 95  mechan 12 
regul 505  protein 90  heart 11 
carcinoma 465  risk 83  interact 11 
role 456  suggest 76  molecular 11 
apoptosi 418  result 74  express 10 
result 405  tumor 73  stiff 10 
function 397  polymorph 70  cardiomyopathi 10 
pathwai 387  ubiquitin 69  studi 10 
dna 384  interact 66  famili 10 
suggest 371  degrad 66  sarcomer 10 
 
2.3.2.2 Construction of Tumor Word Vectors 
Word vectors were created for each of the 2,396 samples in the dataset by combining the 
word vectors for the genes associated with each sample. The average length of the word vector 
for each tumor varies depending on the semantic data source used, and can be found in Table 
2-3. If we consider the average length of the word vectors as a measure of the amount of 
information they contain, then we can gauge the relative quality of the data sources. By 
comparing the numbers we can see that gene summaries on their own provide the least 
information, and GeneRIF and gene summaries combined provide the most. Based on this, and 
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the gene word vectors, we decided to focus on using either PubMed articles or the combination 
of GeneRIF and gene summaries as a data source. 
 
 
Table 2-3. Average length of cancer sample word vectors using different data sources 
Data Source Average Length 
PubMed 980.1703 
GeneRIF 1483.7859 
Gene Summary 508.7003 
GeneRIF and Gene Summary 1627.5776 
 
2.3.3 Topic Modeling Results 
The goal of using topic modeling is to capture recurrent semantic themes (defined by a set of 
commonly co-occurring words) that exist in text documents representing SGAs in a collection of 
tumors. Presence of such a theme in the corpus usually is due to the repeated occurrence of 
SGAs in tumors that share a common functional description (although different genes). The 
settings used to generate the topic models resulted in a hierarchical tree that contains a maximum 
of 210 topics. However, since the algorithm may not utilize all of the topics when learning the 
hierarchical structure, the actual number of topics used can vary across the models. Table 2-4 
lists the average number and standard deviation of topics used over 10 runs of the nHDP 
algorithm for the two data sources, and the two word vector generation methods described in 




Table 2-4. Average number and standard deviation of topics used across different sources and word vector 
generation methods 
Data Source and Word Vectors Average Length Standard Deviation 
PubMed Tf-Idf 201.1 4.508 
PubMed Adjusted Tf-Idf 186.4 6.381 
GeneRIF and Gene Summary Tf-Idf 195.6 5.680 
GeneRIF and Gene Summary Adjusted Tf-Idf 202.4 4.222 
 
 
Each of the topics has different word associations, which can be used to gain a better 
understanding of the types of functions and genes that are associated with the topic. We 
inspected the words that constitute the topics and the SGAs associated with them, and an 
example topic is shown in Figure 2-2. It is clear this topic is related to BRCA1/2 genes and their 
relationship to cancer, particularly breast and ovarian cancers. The main function of BRCA1/2 is 
related to DNA repair, and we found words related to DNA repair in the topic but they did not 
rank high enough to be shown in the figure, which only shows the top 20 words. Interestingly, 
RAD51 gene, another DNA-repair gene that binds with BRCA2 [113] and is regulated by BRCA1 
[114], is ranked high, indicating that the nHDP model was able to capture the DNA-repair theme. 
Similarly, three genes that are strongly associated with this topic are BRCA1, BRCA2 and TP53; 





Figure 2-2. Example topic associations. The top 20 words and SGAs for topic #84 are shown. On the left 
are the words associated with the topic, and on the right are the SGAs that are associated with the topic. In the center 
are the word cloud representations of the words and genes, on the top and bottom respectively. 
 
2.3.4 Clustering Tumors 
Clustering tumors allowed us to compare between using genetic alterations directly and using the 
topic model. We found that clustering based on altered genes did not result in clean clusters for 
any of the cluster sizes (Figure 2-3A). In comparison, there was much clearer separation in the 
tumors for all of the different datasets used when clustering by topic associations. This indicates 
that there was too much noise and variability to be able to cluster samples using the genetic data 
directly. On the other hand, the clearer separation using the topic association indicates that the 
topic generated contains additional information learned about the relationship between genes. 
The clustering result using topics generated with GeneRif and gene summary data with altered tf-
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idf scores for gene names shown in Figure 2-3B. The results shown has 8 clusters, however one 







Figure 2-3. Clustering of tumors. A) Samples were clustered using genomic alteration data. B) Samples 
were clustered using topic associations generated using GeneRif and gene summary data with altered tf-idf scores 
for gene names. 
 
2.3.5 Visualizing Tumors 
Using t-SNE to visualize the tumors allowed us to see how well the topic representation was able 
to separate them. We visualized the tumors using the topics generated with GeneRif and gene 
summary data with altered tf-idf scores for gene names. When we labeled the tumors based on 
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the 8 clusters generated, there was a fairly clear separation of the different clusters (Figure 
2-4A). In comparison, labeling the tumors by cancer type shows that there is not a clear 
separation of cancer types (Figure 2-4B). This supports the theory that different tumors of the 
same cancer type may have different disease mechanisms that lead to the development of cancer, 
and these disease mechanisms may instead be shared by tumors of other cancer type.  
 
2.3.6 Topic to Cluster Associations 
A key motivation of employing nHDP, instead of other probabilistic topic models such as the 
LDA model, is that nHDP not only detects recurrent themes but also, importantly, the covariance 
structure of topics. In other words, if a topic represents a pathway perturbed by SGAs, nHDP can 
capture the combinatorial patterns of pathway perturbations. We examined and illustrated the 
example topic allocation trees (Figure 2-5). Apparently, the pattern of topics associations 
differed between clusters, and certain subtrees are strongly associated with one cluster but not 
the other. This implies that the combination of semantic (functional) themes, rather than the 
possession of unique functional themes, is what separates the different clusters.  While we found 
that many topics would show up in multiple clusters, there are other more specific topics that are 
exclusive to one cluster. This was expected, because the topics that are higher in the hierarchy 
are more general and could be shared across clusters. However, the topics deep in the hierarchy 








Figure 2-4. Visual representation of distance between tumors. Topic representations were used to 
calculate the t-sne distance between individual tumors. A) Tumors are labeled based on the clusters identified in 
section 0 and seen in Figure 2-3B. B) Tumors are labeled based on their cancer type. 
 
2.3.7 Survival Analysis 
Assuming that different clusters consist of tumors sharing common disease mechanisms, we 
performed survival analysis to determine if such subtyping reveals clinical differences. Using the 
8 clusters generated in section 2.3.4 to group the tumors, we performed survival analysis on each 
of the different cancer types. Of the five cancer types, BRCA, HNSC, and LUSC were all found 
to be significant (S Table 1). This was true both when all samples and clusters were used, and 
when only the clusters containing at least 25 samples were used. The resulting survival curves 
can be seen in Figure 2-6. These results indicate that semantic representation and clustering 
revealed cancer subtypes that have significantly different tumors with biologically different 







Figure 2-5. Graphical visualization of cluster-to-topic associations. The calculated degree of cluster-to-
topic associations for two of the clusters using the clustering results seen in Figure 2-3B. These visualizations show 
the structure of the topic tree, where each node represents a topic. The color scale denotes the proportion of tumors 
in a cluster associated with each topic, where white means that none of the tumors in the clusters are associated and 
black means that all of the tumors are associated with the topic. The visualization for the topics associated with 













Figure 2-6. Survival analysis of tumors. The survival analysis curves calculated using only the clusters 
that contain at least 25 samples. A, B, and C correspond to cancer types BRCA, HNSC, and LUSC respectively. 
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2.4 DISCUSSION 
In this study, we investigated the utility of semantic representation and topic modeling for 
identifying combinatorial patterns in signaling pathway perturbations in different tumors. Our 
results show that semantic representation of SGAs makes it possible to detect the functional 
similarity of different genes, which in turn enabled nHDP to detect recurrent combinatorial 
patterns of pathway perturbation. Interestingly, this approach enabled us to identify cancer 
subtypes (clusters) consisting of tumors with quite diverse tissues of origin, which exhibit 
significantly different clinical outcomes (survival). 
To our knowledge, this is a novel approach to studying common disease mechanisms 
using genomic alteration data. Our approach is the first to generate semantic representations to 
capture the functional information of tumors. We conjecture that the existence of topics in this 
new representation is due to recurrent SGAs that perturb genes involved in a common biological 
process or pathway. As such, one can further hypothesize that the presence of a topic in a tumor 
represents that a specific pathway is perturbed in the tumor. Following the same vein of thinking, 
one can hypothesize that tumors within a cluster identified in this study share a common disease 
mechanism, i.e., they share a particular combinatorial pattern of pathway perturbation. Further in 
depth analysis of topics and associated SGAs is needed to examine if such a hypothesis is 
supported by the results. If proved to be the case, our finding can potentially guide therapy 
targeting specific combination of pathways.  
This study also has its limitations. Semantic data is limited by the amount and breadth of 
research available, so genes that are not well research or functions that have not been discovered 
would not be properly represented. This was seen with some of the semantic datasets tested, 
where there may be too much noise or being represented by a limited number of words. Using 
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semantic data also means that the topics generated are composed of words, which makes it 
difficult to identify the underlying genes that led to these associations. While the fact that we 
were able to identify patterns shared across multiple cancer types is promising, the input data is 
limited to only five cancer types. 
2.5 CONCLUSION 
Our research is the first time semantic representations are applied in this way to represent cancer 
samples, as well as the first use of a hierarchical topic model in this aspect of biomedical 
research. Applying topic modeling to the semantic representations of tumors made it possible to 
identify combinatorial patterns of perturbed pathways in cancer tumors. This enabled the 
identification of cancer subtypes containing different tissues of origin that exhibit significantly 
different survival outcomes. If these subtypes are shown to share combinatorial patterns of 





3.0 SEMANTIC MODELING OF DRIVER GENOMIC ALTERATIONS TO 
IDENTIFY PATHWAY PERTURBATION PATTERNS IN CANCER 
3.1 INTRODUCTION 
In the previous study, we found that it was possible to identify cancer subtypes that exhibit 
distinct clinical outcomes through the application of semantic representation and topic modeling 
to tumors of a limited number of cancer types. We wanted to determine if the methods were 
capable of identifying pathway perturbations shared across different cancer types for a larger 
pan-cancer dataset. This would simplify the process of identifying shared features and treatment 
methods across different cancer types. However, increasing the number of cancer types means 
that the number of somatic genomic alterations (SGAs) would also increase.  
We had tried to limit the mutated genes to potential drivers using Polyphen-2, by only 
keeping the genes that were predicted to have a functional impact. However, just because a 
mutation may impact the function of a gene, that does not mean the resulting functional change 
would drive the development of cancer. This tool also cannot be used to evaluate copy number 
alterations. It appeared that the topic modeling algorithm was able to further screen the SGAs by 
identifying those that had functions with a biological impact. However, the topic modeling 
algorithm isn’t designed to identify driver genes, and so it is only able to filter out the less 
common passenger alterations. Even though topic modeling should continue to filter out non-
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driver SGAs, adding additional cancer types increases the difficulty of identifying combinations 
of altered pathways in tumors. Therefore, it may be useful to limit the input to cancer drivers, 
which would allow the topic modeling algorithm to work with an input that contains less noise. 
To focus on these questions, we continued using both the semantic representations we 
developed previously and topic modeling. We expanded the dataset from 5 cancer types to a total 
of 17 different cancer types. In order to study the impact of using drivers as input in lieu of all 
SGAs, drivers were identified using a Bayesian network-based framework. The results were 
compared using cluster and survival analysis. The conceptual overview of our research for the 
driver dataset is shown in Figure 3-1, while the overview of our research for the SGA dataset is 




Figure 3-1. Conceptual overview of research for the driver dataset. A) Somatic mutation, copy number 
alteration, and gene expression data for each tumor was collected. B-C) The genomic alteration data was used as 
input for the tumor driver identification algorithm in order to identify the drivers associated with each tumor.  D) 
Generif and gene summaries associated with genes were collected. E) The semantic data associated with each gene 
was processed to create a word vector representation. F) A document representation for each tumor was created by 
combining the word vectors of each driver associated with the tumor. G) The document representations were used as 
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input for a hierarchical topic model, which identified topics associated with each tumor. H-I) The generated topic 
associations were used to cluster the tumors. 
3.2 METHODS 
3.2.1 Data Processing 
3.2.1.1 Cancer Genomic Data 
Cancer somatic mutation data was downloaded from The Cancer Genome Atlas (TCGA) 
[25]. Copy number variation GISTIC2 results and three different platforms (RNASeqV2, 
RNASeq, and Microarray) for gene expression data were downloaded from Broad GDAC 
Firehose [115]. Pan-cancer data covering 17 different cancer types was used: bladder urothelial 
carcinoma (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), 
esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell 
carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell 
carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung 
squamous cell (LUSC), ovarian serous cystadenocarcinoma (OV), prostate adenocarcinoma 
(PRAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), thyroid 
carcinoma (THCA), and uterine corpus endometrial carcinoma (UCEC). 
3.2.1.1.1 Somatic Mutations 
The somatic mutation data downloaded was classified into 11 different types, with three 
general categories: insertions, deletions, and mutations. We considered all non-synonymous and 
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non-silent mutations to be functional mutations (S Table 2). As such, the only type of mutation 
that was treated as non-functional was silent mutations. Based on the functional call of each 
gene, a binary vector representation for each cancer sample was generated. Each cancer sample 
was represented by multiple genes, where a 1 represents that a functional mutation has occurred, 
and a 0 represents that a functional mutation has not occurred. 
3.2.1.1.2 Copy Number Variation 
GISTIC2 thresholds the copy number variation data for each gene in a cancer sample to 
one of five levels: -2, -1, 0, 1, or 2. These levels represent homozygous deletion, single copy 
deletion, diploid normal copy, low copy number amplification, and high copy number 
amplification respectively. Since we wanted to consider genes that are more likely to have a 
functional impact, we only treated the genes with homozygous deletions (-2) or high copy 
number amplifications (2) as copy number alterations. 
These genes were further filtered to eliminate the genes that were not consistently deleted 
or amplified across different tumors in a specific cancer type. The reasoning behind this is that if 
a gene perturbation has a functional impact on cancer development, then this gene should be 
consistently altered. For example, deletion of a tumor suppressor gene would promote cancer 
development, therefore we would expect to see that the gene has consistently undergone 
deletions in tumors instead of amplifications. As such, we discarded genes that were not 
consistently deleted or amplified. We calculated the ratio of number of tumors amplified to 
number of tumors deleted, and discarded any gene that had a value greater than 1:3 or smaller 
than 3:1. A binary vector representation for each cancer sample was generated. Each cancer 
sample was represented by multiple genes, where a 1 represents that a copy number alteration 
has occurred, and a 0 represents that a copy number alteration has not occurred. 
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3.2.1.1.3 Gene Expression Data 
There is gene expression data for three different platforms available on TCGA: 
RNASeqV2, RNASeq, and Microarray. RNASeqV2 is the most frequently used platform for 
measuring gene expression of TCGA tumors, with a smaller portion of tumors being measured 
by the other two platforms. All of the gene expression datasets for each cancer type were 
downloaded. For each cancer type, we picked the platform that covered the largest number of 
tumors and also contained measurements for normal samples. Measurements for normal samples 
were needed for their use in determining which genes were differentially expressed. Prior to 
analysis, any gene expression value in RNASeqV2 or RNASeq data that was less than 20 were 
considered noise. In normal data, we set these values to 20 before calculation; in tumor data, we 
considered these genes to have normal expression and excluded them from further analysis. 
For each cancer sample, we were only interested in the genes that had an altered 
expression. In order to identify the differentially expressed genes (DEGs) for each sample, the 
expression level of genes in tumors were compared against normal cells of the corresponding 
tissue type. For the genes whose expression in normal cells followed a Gaussian distribution, we 
used their mean and variance to calculate the p-values for each gene in each cancer sample. If the 
p-value fell within a 0.05 threshold on either tail, then the gene was considered to be 
differentially expressed in the corresponding cancer sample. For the genes that did not follow a 
Gaussian distribution due to low variance (less than 0.1), we used fold change to determine 
differential expression. Fold change was calculated by dividing the gene expression of the tumor 
cell by the average expression of the normal cells. Any gene that was determined to have 
undergone a 3-fold change was considered differentially expressed. 
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We wanted to identify the DEGs that were driven by somatic mutations. Therefore, all 
genes that underwent amplification or deletion were not considered differentially expressed. This 
eliminated the chances that gene differential expression was the result of copy number 
alterations. A Pearson correlation analysis was performed to identify tissue specific DEGs that 
were correlated with cancer type or tissue of origin. Any DEG with a correlation value larger 
than 0.9 was removed. A binary matrix representation for all tumors was generated. Each cancer 
sample was represented by multiple genes, where a 1 means that the gene is differentially 
expressed, and a 0 represents that the gene is not differentially expressed. 
3.2.1.1.4 Combined Data 
The somatic mutation and copy number variation representation data were combined to 
form a binary somatic genomic alteration (SGA) matrix, where 1 represents a somatic mutation, 
copy number alteration, or both, and 0 represent that neither have occurred. In order to minimize 
redundant SGA information, SGAs with similar patterns were grouped together. We first merged 
neighboring genes to form a SGA unit when the co-occurrence of their SGAs over the union of 
tumors was larger than 0.9. We then grouped genes or SGA units into SGA groups if they shared 
the exact same SGA pattern. 
3.2.2 Cancer Driver Data 
We used driver data that was calculated and generated by other members in our lab. This 
algorithm to predict the causal relationship between SGAs and DEGs for individual tumors is a 
Bayesian network-based framework developed in our lab [116]. We assume that individual 
DEGs may be caused by individual SGAs, though it is possible that some are caused by non-
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SGA factors. Using initial stricter assumptions that SGAs on a common pathway are mutually 
exclusive and a DEG is the result of one altered pathway, then it can be assumed that a DEG is 
most likely caused by one SGA. The problem of identifying driver SGAs and their associated 
DEGs was represented as a tumor-specific model using a bipartite causal Bayesian network with 
two sets of variables 𝐴𝑠𝑒𝑡 and 𝐺𝑠𝑒𝑡, where causal edges can be added from variables in 𝐴𝑠𝑒𝑡 to 
𝐺𝑠𝑒𝑡 (Figure 3-2). 𝐴𝑠𝑒𝑡 is composed of all SGAs in the given tumor, as well as a “leak node” to 
represent non-SGA factors. 𝐺𝑠𝑒𝑡 is composed of all DEGs in the given tumor. The algorithm 
learns the structure of the Bayesian network for each tumor, based on the SGAs and DEGs for 









∑ 𝑃(𝐷|𝑀) ∗ 𝑃(𝑀)𝑀
 
where the sum is taken over all possible models. The term 𝑃(𝑀) denotes the prior probability 
that the Bayesian network has M as its structure. The term 𝑃(𝐷|𝑀) can be derived as follows: 
𝑃(𝐷|𝑀) = ∫ 𝑃(𝐷|𝑀, 𝜃) ∗ 𝑃(𝜃|𝑀)𝑑𝜃
𝜃
 
where 𝜃 represents the parameters associated with M. 
The driver identification algorithm was run using the generated SGA and DEG binary 
matrices as input. A binary matrix representation for all tumors was generated using the drivers 
identified by the algorithm. Each cancer sample was represented by driver genes, where a 1 
means that the gene is considered a driver for that sample, and a 0 means that the gene is not 
considered a driver.  
 65 
 
Figure 3-2. Tumor-specific driver identification structure. A bipartite Bayesian network that represents 
a hypothesis about which SGAs are causing which DEGs. In this network, A1 represents a driver gene for G2, G3, 
and G4. A2 represents a passenger gene. 
 
3.2.3 Representation of Genes and Tumors 
3.2.3.1 Semantic Representation of Genes 
The data that was downloaded and used to generate the semantic representation of genes 
were the same as those described in section 2.2.2.1. The processing and calculations were also 
performed in the same way. 
3.2.3.2 Semantic Representation of Tumors 
Two different sets of semantic representations were generated for the tumors. The first set 
used all of the SGAs associated with each cancer tumor. The second set used only the identified 
driver genes associated with each cancer tumor. Here we expanded the driver SGA units or 
groups back to their component genes. This is because we only had semantic representations of 
individual genes, and would not be able to directly represent a set of genes. The tumor 
representations generated for these datasets were different, because of the differences in the total 
number of genes in the dataset. 
        
            
A0 A1 A2 A3 
G1 G3 G4 G5 G6 G2 
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Word vectors containing relevant words and their term frequencies were generated for the 
topic modelling process. Word document (gene) frequency and normalized tf-idf scores were 
used to limit the vocabulary size both across the entire dataset and for each gene. The normalized 
tf-idf score for a word was calculated by dividing the cumulative tf-idf score by the number of 
genes the word appears in. We first trimmed the words that occurred in less than a set threshold 
number of genes. The thresholds we used were 26 words for the SGA dataset, and 3 words for 
the driver dataset. We then further trimmed the vocabulary by removing the 1,500 words with 
the smallest normalized tf-idf scores. Trimming the vocabulary allowed us to remove words that 
were too common and too rare to provide useful information in the topic modeling process; it 
also limits the number of features in the modeling process.  
In order to create the word vector associated with a tumor, we utilized only the genes or 
drivers positively associated with that sample (has a value of 1). For each sample, we combined 
the word vectors for all of the positively associated genes in the tumor. During the process, if a 
gene word vector contained its own gene name or alias, then the tf-idf score was altered. We set 
this altered score to be equal to the smaller of the following two values: the highest tf-idf score 
associated with that gene, or 1.5 times the second highest tf-idf score. The values for each word 
in a tumor word vector were set by summing the tf-idf scores for the word across all the genes 
with word vectors containing the word.  
3.2.4 Topic Modeling 
Both the topic modeling algorithm and the topic model selection process were the same as those 
described in section 2.2.3. The algorithm was run on the two corpuses of tumor word vectors, 
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which resulted in a set of word-to-topic and document-to-topic distribution matrices for each 
corpus. 
3.2.5 Analysis 
3.2.5.1 Evaluating Semantic Representation of Genes 
We wanted to determine if genes with similar functions had word vector representations 
that were closer in similarity, in order to ensure that the semantic representation captures the 
functional similarity of genes. Cosine similarity was used to measure the similarity between gene 
word vectors. We used the genes on the KEGG pathway hsa05200 (pathways in cancer) to obtain 
our list of functionally related genes [117, 118]. An equal number of randomly selected genes 
was used as our list of functionally unrelated genes. The cosine similarity of each pair of genes 
for each list was calculated. The cosine similarity distribution for both lists were compared using 
the Wilcoxon rank sum test to determine if there was a significant difference between 
functionally related and unrelated genes. 
3.2.5.2 Calculating Topic to Gene Associations 
The method used to calculate the topic to gene associations was the same as in section 
2.2.4.1. Only the top 20 genes associated with a topic that have an association score of at least 
0.001 were used for further analysis. 
3.2.5.3 Topic Analysis 
In order to have a quantitatively comparable method of measuring the functional 
similarity of the genes associated with the generated topics, we chose to use the protein-protein 
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interaction (PPI) ratio. For a list of genes, this ratio measures the number of existing PPIs over 
the total number of possible interactions. The idea is that functionally similar genes would have a 
greater number of PPI when compared to randomly selected genes, and so would have a larger 





where I is the number of interactions in the gene set, and g is the total number of genes in the 
gene set. Human PPI data version 3.4.127 was downloaded from BioGrid [119]. 
The PPI ratio was calculated for the genes associated with each topic. For each gene list 
length, we generated random gene lists of equal length by randomly selecting from the list of all 
SGAs for the SGA dataset and the list of all drivers for the driver dataset. A total of 10,000 
random draws were obtained for each length, which was used to create a PPI ratio distribution 
for random genes. For each topic, we determined where the PPI ratio fell in the random 
distribution by counting the number of values that were smaller than the calculated topic PPI 
ratio. Dividing this count by the number of samples gave us the proportion of randomly 
generated PPI values that the topic PPI ratio was larger than. 
3.2.5.4 Clustering Tumors 
We performed consensus clustering on the tumors to determine if relationship 
information was learned from the data by using topic modeling. As such, clustering was 
performed while using as input the SGA dataset directly, the driver dataset directly, the word 
count per topic associations generated using the SGA dataset, and the word count per topic 
associations generated using the driver dataset. We used partitioning around medoids (PAM), k-
means, and merging the two for consensus as the clustering methods. The algorithm was run for 
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cluster sizes 10-25 when clustering directly based on SGAs or drivers, and cluster sizes 10-30 
when clustering based on the word count per topic associations. Consensus clustering was 
performed using the clusterCons package version 1.0 in R [109]. 
3.2.5.5 Cluster Evaluation 
We used the gene alterations associated with each cluster in order to evaluate if the 
samples share common combinations of pathways. These gene lists were used to calculate 
protein-protein interaction ratios. The reasoning is that genes sharing pathways would have a 
larger number of protein-protein interactions than unrelated genes. As such, if tumors share 
common combinations of pathways, then there should be more PPI between their genes than 
samples with combinations of pathways that are unrelated. For the clusters generated using either 
dataset, the SGA list for each cluster was obtained by compiling all of the SGAs associated with 
each cancer sample in a cluster. For the clusters generated using the driver dataset, the driver list 
for each cluster was obtained by compiling all of the drivers associated with each cancer sample 
in a cluster. The method of calculating the PPI ratio and comparing against the random 
distribution was the same as described in section 3.2.5.3. A total of 10,000 random draws was 
used to generate the random distribution for gene list length. 
3.2.5.6 Visualization of Tumor Clusters 
The topic representation of the tumors was visualized in a two-dimensional space using 
the same methods as those described in section 2.2.4.3. 
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3.2.5.7 Survival Analysis 
The biological impact of subtyping the tumors based on clustering was measured by 
performing survival analysis on each cancer subtype separately. Survival data for the tumors was 
obtained from the TCGA project clinical data using the National Cancer Institute’s Genomic 
Data Commons: http://gdc.nci.nih.gov/. The survival analysis was performed using the same 
method as those described in section 2.2.4.5. The only change made was to exclude any cluster 
that contained less than 20 samples when analyzing each individual cancer type.  
3.3 RESULTS 
3.3.1 Cancer Data 
For the 17 different cancer types downloaded, when we kept the tumors that had both somatic 
mutations and copy number alteration data available, we had a total of 5608 tumors. The 
breakdown of the number of samples in each cancer type is listed in S Table 3. This data resulted 
in a total of 38,004 SGAs. This final SGA to sample mapping was used as the somatic genomic 
alteration (SGA) dataset. 
When we restricted the samples by the copy number alteration data, we had a total 4468 
tumors. This also resulted in the removal of THCA data, because of the quality copy number 
alteration data. The breakdown of number of samples in each cancer type is listed in S Table 3. 
This data resulted in a total number of 26,203 SGAs. From this genomic data we obtained a final 
list of 721 identified drivers, with any SGA unit or group being treated as an individual driver. If 
we expand these SGA units or groups back to their component genes, we obtain a list of 733 
 71 
genes. This final gene to sample mapping was used as the driver dataset. Given that two different 
cancer sample gene association datasets were used, the SGA dataset and the driver dataset, a 
different semantic representation was generated for each. 
3.3.2 Semantic Data 
The initial vocabulary size for the SGA dataset was 167,314 words. Of the 26,203 SGAs there 
were 8,724 that had less than 5 words associated. After trimming the vocabulary, we had a final 
size of 6,396 words. This also resulted in 859 new genes that had less than 5 words associated. 
However, we felt that this increase was acceptable because it accounted for less than 5% of the 
genes that previously had more than 5 word associations (4.91%). 
Similarly, the initial vocabulary size for the driver dataset was 31,869 words. Of the 733 
genes there were 146 that had less than 5 words associated. After trimming the vocabulary, we 
had a final size of 6,029 words. This resulted in 21 new genes that had less than 5 words 
associated. Once again, this accounted for less than 5% of the genes that previously had more 
than 5 word associations (3.78%). 
3.3.2.1 Semantic Representation Evaluation 
The vector representations of genes were used to calculate and compare the distribution of cosine 
similarities for random gene pairs when compared to the genes on the KEGG pathway named 
pathways in cancer [117, 118]. We found that there was a significant difference between the 
random and KEGG distributions both when we used the SGA dataset and when we used the 
driver dataset for calculation (Figure 3-3). The Wilcoxon rank sum p-value were 0 and 5.8e-124 
for the SGA and driver dataset respectively. Having the cosine similarity distribution for 
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functionally related gene pairs be greater than the random gene pairs supports the idea that the 
semantic representation captures functional information. We believe that the driver genes would 
result in a less significant difference because the driver genes have all been predicted to be 
relevant to the development of cancer. As such, randomly selecting driver gene pairs would be 
more likely to have functional relevance than when randomly selecting from all SGAs. A subset 
of the words, with their tf-idf scores, from an example driver gene pair with a high cosine 
similarity score is given in Table 3-1. Words that occur in both vectors are highlighted in red. 
Both PIK3CA and PTEN are involved in the same pathway, with PIK3CA being a known 
oncogene and PTEN being a known tumor suppressor. This highlights the ability of semantic 







Figure 3-3. Cosine similarity distributions of semantic representations of genes. The cosine similarity 
was calculated for pairs of genes on a KEGG pathway, and the same number of pairs of random genes. The resulting 
distribution for the KEGG genes can be seen in red, and random genes can be seen in blue. A) All SGAs in the 
pathway were compared with genes randomly selected from all SGAs. B) All drivers in the pathway were compared 
with genes randomly selected from all drivers. 
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Table 3-1. Subset of words from two word vectors with one of the highest cosine similarity scores 
PIK3CA  PTEN 
Word Tf-Idf  Word Tf-Idf 
pik3ca 416  pten 262 
pi3k 416  akt 175 
mutat 220  cancer 156 
akt 155  cell 153 
cancer 118  tumor 130 
pathwai 100  express 129 
pten 82  carcinoma 109 
activ 76  mutat 107 
kra 73  pi3k 98 
cell 65  pathwai 93 
signal 63  activ 81 
breast 59  endometri 78 
carcinoma 53  signal 75 
3-kinas 53  prostat 75 
tumor 52  breast 67 
oncogen 50  phosphatas 65 
braf 49  pik3ca 57 
akt1 45  associ 57 
patient 41  promot 54 
endometri 38  patient 51 
 
3.3.3 Topic Modeling Results 
The structure of the tree and the topics were inspected, and some example topics from the topic 
associations calculated using the driver dataset are shown in Figure 3-4. Figure 3-4A shows the 
full structure of the topic model tree, while Figure 3-4B is a look at one specific branch. The 
topics shown (Figure 3-4C-E) span one branch from the root to the leaf. This reveals that the 
words in topics closer to the root are more general, containing common words such as cancer, 
tumor, and cell. As we move further down the branch, the words get more specific. One other 
aspect to note is that GATA proteins are known to regulate mucin genes [120]. The fact that 
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these words appear in topics along the same branch indicates that the hierarchical structure is 




Figure 3-4. Topic model structure and topic associations. The hierarchical structure and example topics 
of a topic model generated using the semantic driver dataset as input is shown. A) The visualization shows the full 
hierarchical structure of the topic tree, where each node represents a topic.  B) One branch along the topic tree. C-E) 
Word clouds showing three example topics that are progressively deeper in the topic tree, and further away from the 
root. These words associated with the topics also are progressively more specific.  
 
3.3.3.1 Topic Analysis 
In order to confirm that the topics have grouped together functionally similar genes, their 
PPI ratios were calculated and compared to the PPI ratios of random gene lists. Functionally 
related genes would have a greater number of PPI than unrelated genes, so the PPI ratio of topic 
genes should be higher if they are functionally related. We found that 98% of the topics for the 
SGA dataset had a PPI ratio larger than at least 95% of those generated at random (S Table 4), 
and the driver dataset had 91% of the topics meet that threshold (S Table 5). This indicates that 
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the topic model is able to identify and capture functional information, and their topic association 
patterns can then be used to separate tumors. 
3.3.4 Clustering Tumors 
Clustering was used to compare the performance of the different datasets in capturing relevant 
information. The tumors were clustered using genomic alterations directly (S Figure 2), drivers 
directly (S Figure 3), and using the topic associations generated based on the SGA dataset and 
the driver dataset (Figure 3-5). We found that clustering based on the genomic alterations was 
unable to generate clean clusters at any of the cluster sizes that were searched. On the other hand, 
clustering directly based on drivers generated clean clusters at all of the cluster sizes that were 
searched. This indicates that a lot of noise was removed through driver identification. However, 
clustering directly using drivers is not capable of grouping together drivers with the same 
functional impact. As for the topic associations, the fact that both topic associations were able to 
generate cleaner clusters indicates that it decreases the amount of noise in the data and captures 
information about the relationship between genes. However, when comparing the driver topic 
association clusters with the driver clusters, it suggests that the semantic representation may be 
adding in some additional noise. The clustering results for the SGA dataset at k = 14 is shown in 
Figure 3-5A. The clustering results for the driver dataset at k = 16 is shown in Figure 3-5B. 
These two clustering results were used to generate 16 and 23 clusters, respectively. 
3.3.4.1 Cluster Evaluation 
With topics grouping together functionally similar genes, when we clustered the tumors 
based on their topic associations the resulting clusters should contain samples that have common 
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perturbed pathways. Tumors with common perturbed pathways would contain genes that have a 
greater number of PPI. As such, a cluster of genes with a PPI ratio greater than the PPI ratios for 
random genes would indicate that the tumors were more likely to share common perturbed 
pathways. We found that all of the clusters for the SGA dataset had PPI ratios that were larger 
than at least 95% of those generated at random (S Table 6). For the driver dataset, 95% of the 
clusters had a driver PPI ratio that was larger than at least 95% of those generated at random (S 
Table 7). However, when we used all associated SGAs instead of just drivers, we found only 
13% to be above the 0.95 threshold (S Table 8). This is likely because the tumor representations 
were based on drivers, and so the topics identified drivers that have similar functions. However, 
the SGAs associated with these tumors contained more noise and extraneous functions. This 
means that the driver representation would not account for these functions. On the other hand, 
the SGA dataset was calculated based on capturing the functional similarity of all genes, even if 







Figure 3-5. Clustering of tumors. Samples were clustered using topic associations generated on the 
somatic genomic alteration (SGA) dataset and driver dataset. A) The clustering results for the SGA dataset at k = 14, 














Figure 3-6. Visual representation of distance between tumors. Topic representations were used to 
calculate the t-sne distance tumors. A and B were generated using the topic associations for the SGA dataset. C and 
D were generated using the topic associations for the driver dataset. A, C) Tumors are labeled based on the clusters 
identified in section 3.2.5.4 and seen in Figure 3-5. B, D) Tumors are labeled based on their cancer type. 
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3.3.5 Visualization of Tumor Clusters 
In order to see how well the topic representations could separate the tumors, they were visualized 
in a 2D space using t-SNE. The tumors were labeled either based on the clusters generated 
(section 3.3.4) or by their cancer type and the results can be seen in Figure 3-6. The clusters are 
not well separated when using the topic associations generated by the SGA dataset (Figure 
3-6A). In comparison, there is a much cleaner separation between clusters when visualizing the 
tumors using the topic associations generated by the driver dataset (Figure 3-6C). This indicates 
that there may be too much noise in the SGA dataset for the topic model to handle. Limiting the 
dataset to the identified driver genes decreased the amount of noise, which would make it easier 
to capture the relevant information about genes. As such, we feel that further research should 
focus on using driver genes, rather than all SGAs, as input. Another observation we had was that 
both representations contained a mixture of cancer types across tumors, which can be seen in 
Figure 3-6B and D. This indicates that disease mechanisms can be shared across cancer types. 
3.3.6 Survival Analysis 
Survival analysis was performed on each of the different cancer types for both the SGA and the 
driver datasets, using 16 and 23 clusters respectively. We found that the majority of the tumors 
did not have a significant difference in survival rates. For the SGA dataset, only KIRC and 
LUSC were found to be significant (S Figure 4); for the driver dataset, only BRCA, LUSC, and 
UCEC were found to be significant (S Figure 5). Different combinations of biological features 
may have been identified using the clustering method, as indicated by a difference in survival 
rates for some cancer types. The fact that different cancer types had significantly different 
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survival rates for the two datasets suggests that different features were found. However, the way 
many of the clusters seem to mix in the t-SNE representation of the SGA dataset makes the 
results less compelling and difficult to interpret. A lack of difference in survival data for some 
cancer types was expected, due to either a lack of adequate survival data or no known difference 
in survival performance. However, the fact that so few cancer types had a significant difference 
still indicates that it may be difficult to detect these different features in a pan-cancer dataset.  
3.4 DISCUSSION 
In this study, we applied and analyzed the use of semantic representation and topic modeling on 
a pan-cancer dataset, and also compared the results obtained when using the SGA dataset and the 
driver dataset as input. Analysis of the results indicates that these methods are capable of 
grouping functionally related genes and finding functional relationships between topics. This 
then allows the clustered samples to be grouped with other samples that have similar functions 
altered. The results indicate that using driver genes leads to a better separation of samples, and a 
different set of survival results. 
Building upon our previous results in Chapter 2.0, we provided further results supporting 
the hypothesis that the semantic representations used detect the functional similarity of genes. 
We also took steps to validate and evaluate our topic and clustering results in a quantitative 
manner. Using t-SNE visualization allowed us to observe the clean separation of clusters using 
the driver dataset, in contrast with the full SGA dataset. This highlights the importance of using 
driver genes in research, even if functional similarity can be captured for all genes. Using driver 
genes decreases the dimensionality of the problem, since prior to driver identification tumors 
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could have as many as 500 or more alterations. A focus on driver genes also means that the 
genes and functions grouped by topics would be related to cancer development, which is not true 
when all SGAs are used. Applying the methods on a pan-cancer scale demonstrated its ability to 
perform on a large scale, which would make it useful for drawing interpretations about cancers 
that span different tissue types. 
Given that this study continues to use semantic data, it is once again limited by the 
amount and breadth of research available. This limitation means that it is difficult to accurately 
represent genes with newly discovered or poorly understood functions. As a result, the grouping 
of some genes to certain topics may not accurately reflect the biological truth. Interpretation of 
the results is also limited by the amount of insight that is gained from the generated topics. 
Without an understanding of what functions are captured by the topics associated with individual 
clusters or samples, it is difficult to draw conclusions about what functions are being altered. The 
quality of the results generated using the driver dataset are also dependent on the accuracy of the 
identified drivers.  
3.5 CONCLUSION 
Our research applied both semantic representation and hierarchical topic modeling to pan-cancer 
data. While semantic representations made it possible to identify functionally similar genes, their 
performance is dependent on available research and literature. Therefore, it may be useful to 
pursue other forms of representation that could capture gene function without this dependency. 
Our results show that driver data lead to an improved performance in cluster separation. Being 
able to better identify the similarities and differences between tumors is potentially useful for 
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understanding and treating cancer. As such, the application of driver data in identifying cancer 
disease mechanisms may be beneficial. 
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4.0 BIOLOGICAL REPRESENTATION OF DRIVER GENOMIC ALTERATIONS 
TO IDENTIFY PATHWAY PERTURBATION PATTERNS IN CANCER 
4.1 INTRODUCTION 
Our prior studies used semantic representations to capture the functional information of genes 
and their associated tumors. However, as mentioned previously, these representations are 
knowledge-driven and dependent on available literature. As such, genes would not be accurately 
represented without literature available covering the relevant functions. This makes it difficult to 
make new discoveries about the functional similarities of genes. Therefore, we wanted to 
develop a representation that is independent of literature and determine how well it performs on 
pan-cancer data. 
In order to tackle this problem and continue to capture the functional similarity of distinct 
genes, we developed a novel biological representation of genes that takes advantage of the driver 
identification algorithm developed in our lab. Gene expression is the compilation of the signaling 
state of cells. Therefore, an alteration that has an impact on gene function would result in a 
signature of differentially expressed genes (DEGs). This means that the functions of driver 
somatic genomic alterations (SGAs) could be represented by the DEGs they have a causal 
relationship with. Using a driver-based representation that is calculated directly from the tumors 
is a data-driven approach, and allows the representation to be more biologically relevant and 
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better fit the dataset than a knowledge-driven approach. It also avoids the bias that is inherent in 





Figure 4-1. Conceptual overview of research. A) Somatic mutation, copy number alteration, and gene 
expression data for each tumor was collected. B-C) The genomic alteration data was used as input for the tumor 
driver identification algorithm in order to identify the driver to gene association for each tumor. D) The driver to 
gene association information was used to generate tumor representations that were used as input for a hierarchical 
topic model, which identified topics associated with each tumor. E-F) The generated topic association were used to 
cluster the tumors. 
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In order to determine if biological representations can be used in conjunction with topic 
modeling to identify combinatorial patterns of pathway perturbations, we applied our novel 
biological representation to pan-cancer data in lieu of the previously used semantic 
representation. We continued using pan-cancer data, and obtained the relationships between 
SGAs and DEGs using the tumor-specific driver identification algorithm. The results were 
evaluated using cluster and survival analysis. The conceptual overview of our research is shown 
in Figure 4-1. 
4.2 METHODS 
4.2.1 Data Processing 
The somatic mutation data was downloaded from The Cancer Genome Atlas (TCGA) [25], while 
the copy number variation and gene expression data were downloaded from Broad GDAC 
Firehose [115]. Since all three data types were needed for analysis, only 16 cancer types were 
used: bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colon 
adenocarcinoma (COAD), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), 
head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), 
kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung 
adenocarcinoma (LUAD), lung squamous cell (LUSC), ovarian serous cystadenocarcinoma 
(OV), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), stomach 
adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC). The 16 
downloaded cancer types resulted in a total of 4468 tumors, and 26,203 SGAs. The breakdown 
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of the samples per cancer type is listed in S Table 3. The methods used for data processing were 
the same as those listed in section 3.2.1. 
4.2.2 Cancer Driver Data 
The driver data containing the driver to gene association for these tumors were calculated in the 
same way as described in section 3.2.2. This resulted in a final list of 721 unique drivers and 
15,902 DEGs.  
4.2.3 Representation of Genes and Tumors 
4.2.3.1 Biological Representation of Genes 
The calculated driver data contained information regarding the relationship between 
somatic genomic alterations (SGAs) and differentially expressed genes (DEGs). This 
relationship was used to generate the biological representation of genes, where each driver SGA, 
SGA unit, or SGA group was represented by its associated DEGs. The SGA units and groups 
were not expanded back to their component genes in order to avoid over-representing these 
drivers since they would all be represented by the same DEGs. A binary vector of DEGs was 
created where a value of 0 meant that the DEG was not associated with the driver, and a value of 
1 meant that the DEG was associated with the driver. Since the driver and DEG associations 
differed depending on the tumor, the representations for the same driver could be different for 
different tumors. 
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4.2.3.2 Biological Representation of Tumors 
Vectors containing the relevant DEGs and their frequencies were needed for the topic 
modelling process. Since the cancer driver identification process already excluded the DEGs that 
were predicted to be irrelevant to cancer development, further limitation of the “vocabulary” size 
was not performed. This resulted in a final vocabulary size of 15,902 genes. For each tumor, the 
DEG vector representation was created by using count vectors and summing up the values of 
each of its drivers.  
4.2.4 Topic Modeling 
The topic modeling algorithm and the topic model selection process were the same as those 
described in section 2.2.3. The nHDP algorithm was run on the corpus of DEG vectors 
representing the tumors in order to generate the resulting word-to-topic and document-to-topic 
distribution matrices.  
4.2.5 Analysis 
4.2.5.1 Evaluating Biological Representation of Genes 
In order to ensure that the biological representation captures the functional similarity of 
genes, we wanted to determine that gene vector representations for drivers with similar functions 
were closer in similarity. Since the driver representation was different for each tumor, a 
comprehensive representation for each driver was generated. This representation was a count 
vector, where the value for each DEG was calculated by counting the number of times the DEG 
was associated with the driver across all tumors. However, the drivers that we have 
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representations of are all predicted to be cancer drivers, which means they are already likely to 
be functionally related. Therefore, for each driver we generated a corresponding random “driver” 
by keeping the counts and replacing the associated DEGs with the DEGs randomly selected from 
the entire “vocabulary”. This random selection represents the situation where the identified 
DEGs do not have any relationship with the driver, and therefore would not be functionally 
related. The subset of an example driver gene vector representation as well as its corresponding 
randomly generated vector can be seen in Table 4-1. 
 
 


































































  Cosine similarity was used to measure the similarity for both the comprehensive and the 
random DEG count vectors. The cosine similarity of each pair of genes within the two 
collections of DEG count vectors were calculated. The cosine similarity distribution for both 
collections were compared using the Wilcoxon rank sum test to determine if there was a 
significant difference between functionally related and randomly generated drivers. 
4.2.5.2 Calculating Topic to Driver Associations 
Since we used the input DEG count vectors as documents, the “words” that the topic 
model selected were actually genes. However, further calculations were necessary in order to 
determine the drivers associated with each topic. The topic to driver associations for each topic 
(t) were calculated using the generated word-to-topic and document-to-topic matrices. The word-
to-topic matrix was normalized by topic to get the probability of each word being associated with 
a topic. For each document (d) and each word (w) in the document, we identified the driver that 
was most strongly associated by extracting row w from the normalized word-to-topic matrix, and 
performing element-wise multiplication of it with row d of the document-to-topic matrix. The 
topic t with the largest value in this resulting vector was identified, and the driver associated with 
word w was assigned to this topic. If the driver was already associated with topic t, then the value 
assigned to the driver would be increased by 1. We chose to use an incremental value of 1 
because it helps to decrease the chance of topics becoming dominated by common drivers, and 
drowning out the signal of rarer drivers. Only the top 20 drivers associated with a topic were 
used for further analysis. 






wordTopicMatrix - matrix containing probability of each word occurring in each topic 
documentTopicMatrix - matrix containing number of words from each document 
associated with each topic 
DEG vector representation of each SGA for each document 
 
Initialize: 
topicDriverMatrix - an empty topic by driver matrix 
 
foreach document (d) 
foreach word (w) 
Perform element-wise multiplication of row w in wordTopicMatrix with row d in 
documentTopicMatrix 
Find the topic (t) with the largest value in resulting vector 
Identify driver (s) associated with w for d 
topicDriverMatrix[t][s] = topicDriverMatrix[t][s] + 1 
 
4.2.5.3 Topic Analysis 
The method for performing topic analysis was the same as that described in section 
3.2.5.3. Prior to running the analysis, any SGA unit or SGA group was expanded, and the 
component genes were used. This is because SGA units and SGA groups cannot be directly used 
to identify protein-protein interactions. As a result, some of the gene lists had a length greater 
than 20.  
4.2.5.4 Clustering Tumors 
Consensus clustering was performed on the tumors to determine if the use of topic 
modeling allowed us to learn additional relationship information about the data. As such, 
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clustering was performed using the generated topic associations. We used partitioning around 
medoids, k-means, and merging the two for consensus as the clustering methods. The algorithm 
was run for cluster sizes 10-30. Consensus clustering was performed using the clusterCons 
package version 1.0 in R [109]. 
4.2.5.5 Cluster Evaluation 
We used the drivers associated with each cluster to evaluate if the samples share common 
combinations of pathways. The driver gene list for each cluster was obtained by taking the union 
of all of the drivers associated with each tumor in a cluster. A total of 10,000 random draws was 
used to generate the random distribution for each driver list length. The reasoning for this 
analysis was provided in section 3.2.5.5, and the method for calculating the PPI ratio and 
comparing against the random distribution was described in section 3.2.5.3. 
4.2.5.6 Visualization of Tumor Clusters 
The topic representations of the tumors were visualized in a two-dimensional space using 
the same methods as those described in section 2.2.4.3. 
4.2.5.7 Calculating Cluster to Topic Associations 
We visualized the proportions of samples in a cluster associated with each topic using the 
same method as section 2.2.4.4. 
4.2.5.8 Survival Analysis 
Kaplan-Meier survival analysis was performed on two different cancer subtypes as a 
measure of biological impact in subtyping the tumors based on clustering: GBM and OV. 
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Survival data for the tumors was obtained from the TCGA project clinical data using the 
National Cancer Institute’s Genomic Data Commons: http://gdc.nci.nih.gov/. Due to the fact that 
clustering the pan-cancer data resulted in clusters mainly being separated by cancer types, 
consensus clustering was performed on the tumors for these individual cancer types separately 
for cluster sizes 4-20. The tumors were separated into subsets based on these newly generated 
clustering results. We used the survival package version 2.38.3 in R to conduct the analysis [111, 
112]. 
4.3 RESULTS 
4.3.1 Biological Representation Evaluation 
The DEG vector representations of drivers and the randomly generated representations 
were used to calculate and compare the resulting cosine similarity distributions. We found that 
there was a significant difference between the random and driver distributions (Figure 4-2). The 
Wilcoxon rank sum p-value was 3.05e-269. This result supports the idea that the DEGs 
associated with a driver SGA have a relationship, and so a biological representation based on 
these DEGs would be able to capture functional information about the drivers. We also identified 
driver pairs that have high cosine similarity, and found that one of the top pairs was KEAP1 and 
NFE2L2 (Table 4-2). These two genes are on the same pathway and play a role in response to 
oxidative stress [121]. This further highlights the ability of biological gene representations to 




Figure 4-2. Cosine similarity distribution of biological representations of genes. Cosine similarity was 
calculated for each pair of driver SGAs and each pair of randomly generated DEG vectors. The resulting distribution 
for the SGAs can be seen in red, and random genes can be seen in blue. 
 
4.3.1.1 Topic Analysis 
To confirm that the topics generated based on biological representations could group 
together functionally similar drivers, the PPI ratios of topic driver SGAs were calculated and 
compared to the PPI ratios of randomly selected driver SGAs. We found that 80% of the topics 
had a PPI ratio larger than at least 95% of those generated at random (S Table 9). This indicates 
that the topic model is able to capture functional information when working with biological 
representations. However, the fact that this is a relatively lower percentage may mean that it is 






Table 4-2. Subset of words from two word vectors with one of the highest cosine similarity scores 
KEAP1  NFE2L2 
Word Count  Word Count 
SLC7A11 121  SLC7A11 129 
AKR1C1 118  PANX2 115 
PGR 114  AKR1C1 104 
NQO1 109  LRP8 100 
CYP4F11 108  SLC12A8 96 
VGLL1 107  TRIM16L 93 
FREM1 107  WNT5A 92 
COL13A1 106  CABYR 91 
ADRB2 106  AKR1B15 87 
CHRNA5 103  AKR1C3 86 
CKMT1B 102  TXNRD1 85 
C6orf97 102  GCLM 78 
WISP2 99  VSIG10L 77 
CABYR 99  GCLC 74 
RBMS3 98  C1orf31 74 
KIAA1529 95  CBR3 73 
TRIM16L 94  ABCC1 73 
CBFA2T3 94  SRXN1 72 
SIGLEC1 89  OSGIN1 72 
AKR1C3 88  CBR1 71 
 
4.3.2 Clustering Tumors 
Consensus clustering was performed to see if the cancer samples could be separated along 
common disease mechanisms identified using biological representations. We found that 
clustering based on the topic associations (Figure 4-3) resulted in cleaner clusters than using 
SGAs directly (S Figure 2), but less so than those using drivers directly (S Figure 3). One 
interesting feature about the clusters generated using biological topic associations is that the 
resulting clusters are generally dominated by one cancer type. The fact that this is seen in 
clusters generated using topic associations, but not those generated directly from driver data 
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indicates that the DEGs associated with each tumor still contains some tissue type specific 
information. This information would get captured through biological representation, but would 




Figure 4-3. Clustering of tumors. Samples were clustered using topic associations generated using 
biological representations of drivers. The clustering result at k = 15 is shown. 
 
4.3.2.1 Cluster Evaluation 
Since we found that topics group together functionally similar genes, clustering samples 
based on these topic associations should result in clusters with common perturbed pathways. We 
found that all of the clusters generated using topic associations had PPI ratios that were greater 
than at least 99% of those generated at random (S Table 10). This indicates that even if the topics 
identified using biological representations do not perform as well at capturing functional 
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information, it is still possible to find the overall combinatorial patterns of pathway perturbations 
when clustering tumors based on these topics. 
4.3.3 Visualization of Tumor Clusters 
Similar to what we saw with the clustering results, the t-SNE projection also revealed a clean 
separation between clusters (Figure 4-4). It even more clearly highlights how the different cancer 
types dominate each individual cluster. This indicates that though the topics used genes to 
capture distinct recurrent themes, these resulting themes were heavily influenced by the tissue of 
origin. This can be due to the fact that the biological representation uses DEGs to represent 
tumors, and some of the DEGs are still influenced by their tissue of origin despite attempts to 
filter out tissue-specific signals. The fact that these tumors were separated based on tissue and 
not just cancer type can be observed where cancers with similar origins, such as colon 
adenocarcinoma (COAD) and rectum adenocarcinoma (READ) or esophageal carcinoma 
(ESCA) and stomach adenocarcinoma (STAD) occur in the same cluster. This just means that 
the tissue-specific expression is the predominate signal identified using the biological 
representation, and it would take a closer look at individual tissue types to see if another 






Figure 4-4. Visual representation of distance between tumors. Topic representations were used to 
calculate the t-sne distance between individual tumors. A) Tumors are labeled based on the clusters identified in 
section 0 and seen in Figure 4-3. B) Tumors are labeled based on their cancer type. 
 
4.3.4 Topic to Cluster Associations 
Since nHDP can detect the covariance structure of topics, we can use it to observe the 
combinatorial patterns of perturbations in different tumors. In Figure 4-5, we illustrated some of 
the example topic allocation trees. When examining these allocation trees, we found that the 
topic association patterns differed between clusters, and that some clusters are mainly composed 
of topics from just one subtree. Since the clusters were dominated by a specific tissue type, this 
implies that the topic model has identified the relationship between tissue-related genes. In these 
topic allocation trees, we see that the general topics that are strongly shared by the samples in a 
specific cluster, whereas the more specific topics deep in the hierarchy are only associated with a 






Figure 4-5. Graphical visualization of cluster-to-topic associations. The calculated degree of cluster-to-
topic associations for two clusters using the clustering results seen in Figure 4-3 are shown here. These 
visualizations show the structure of the topic tree, where each node represents a topic. The color scale denotes the 
proportion of tumors in a cluster associated with each topic, where white means that none of the tumors in the 
clusters are associated and black means that all of the tumors are associated with the topic. A) The visualization for 
the topics associated with cluster 6. B) The visualization for the topics associated with cluster 9. 
 
4.3.5 Survival Analysis 
Even though clustering of pan-cancer data resulted in clusters dominated by individual cancer 
types, we still wanted to see if biological representations could be used to separate tumors by 
disease mechanisms that result in clinical differences. Since different cancer types have different 
survival rates and cannot be compared directly, we chose to look further into GBM and OV and 
clustered these samples separately before performing survival analysis on the results. We found 
that the two cancer types had a p-value of 0.0356 and 0.0826 respectively. These results indicate 
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that the topic associations may have captured some clinically relevant features. However, since 
clustering was performed on the topic associations generated using pan-cancer data, the topics 
may not be able to capture the information relevant to a specific cancer type as cleanly. This 








Figure 4-6. Survival analysis of tumors. The survival analysis curves calculated using the clusters 
generated when clustering GBM and OV tumors separately. The curves correspond to A) GBM and B) OV. 
 
4.4 DISCUSSION 
We investigated the ability to use biological representations and topic modeling to identify 
combinatorial patterns in perturbed signaling pathways of different tumors. Our results show that 
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it is possible to detect the functional similarity of different drivers using a biological 
representation. This allowed nHDP to identify patterns in pathway perturbations across different 
cancer types. In contrast with the semantic representations, the tumors were generally clustered 
based on tissue of origin. As such, two of the cancer types were separately clustered and GBM 
was found to have significantly different survival rates.  
To our knowledge, this is the first time a biological representation has been used to 
represent genes or tumors. We also show its ability to differentiate between functionally similar 
and random genes. Despite the fact that a smaller portion of the generated topics were considered 
functionally coherent, the topic associations could still be used to find combinatorial patterns in 
the pathway perturbations of tumors. This is where we found a very contrasting difference from 
when we used semantic representations, clusters were generally dominated by a specific cancer 
type or tissue of origin. These results highlight a problem that would need to be tackled if 
biological representations will be used in pan-cancer analysis: the differential expression of 
genes is affected by both tissue of origin and cell type. Until this issue is handled, biological 
representations can only be effectively used on a smaller-scale analysis of cancer types. 
However, the fact that there was a significant different in survival for one of the two cancer types 
we evaluated indicates that the biological representation is still capable of detecting differences 
between tumors of the same cancer type. 
The biological representation that we developed was based on identified drivers and their 
causal relationships with DEGs. As such, the accuracy of the representation is dependent on the 
accuracy of the identification results. An inaccurate identification could result in either the wrong 
driver being represented by the DEGs, or a driver being represented by the wrong set of DEGs. 
The current method of representation also has done little to trim or limit the DEGs that are used. 
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As such, the current iteration may result in a situation where the tumors are represented by 
almost all of their DEGs. This may help explain why there is such a clear separation between the 
different cancer types. Also when we worked on analyzing individual cancer types, we used the 
topic associations generated using pan-cancer data. Since the topic model was capturing the 
features from a larger dataset, the topics generated may be too general and have a hard time 
capturing the finer differences between tumors of a specific cancer type.  
4.5 CONCLUSION 
In this study we developed a biological representation of genes and tumors that we paired with 
hierarchical topic modeling and applied to pan-cancer data. The biological representations were 
data-driven and able to identify functionally similar genes, with their accuracy dependent on the 
predicted causal relationships between SGAs and DEGs. This representation seems to be 
dominated by tissue-specific signals, which resulted in clusters that were dominated by a single 
tissue of origin.  However, analyzing two of the cancer types individually lead us to find that one 
of them still had significantly different survival rates. Therefore, a biological representation 
could still be used to identify clinically relevant features. 
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5.0 OVERALL DISCUSSION 
This dissertation focused on studying the utility of using alternative representations of genes and 
tumors in conjunction with hierarchical topic models for identifying combinatorial patterns of 
pathway perturbations in cancer. The effect of using driver data in the process was also studied. 
The results show that both semantic and biological representations are valid methods of 
capturing the functional similarity of genes, and the methodology we developed is worthy of 
further exploration with multiple examples of tumors in a cancer type being separated into 
groups with different survival outcomes. 
We initially started off with an evaluation of the feasibility of using semantic 
representations of tumors and topic modeling for cancer analysis. While vector representation of 
genes had previously been used, to our knowledge, this is the first time that they have been 
combined and used to represent tumors. This was also the first time hierarchical topic modeling 
was used for cancer research, and further the first use of the nested hierarchical Dirichlet process 
(nHDP) in the biomedical field. We found that these methods made it possible to separate tumors 
into clear clusters based on their topic association patterns. If these topics represent pathways 
perturbed by somatic genomic alterations (SGAs), then nHDP makes it possible to detect 
patterns of pathway perturbations. The fact that the majority of the cancer types have 
significantly different clinical outcomes indicates that clinically relevant features are being 
captured by this methodology.  
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In order to further explore the abilities of this methodology, we applied it to pan-cancer 
data. At this time our lab had developed an algorithm for identifying cancer drivers, which is a 
major aspect of cancer research. We were interested in seeing what type of impact the inclusion 
of driver data would have, and so we compared the results obtained when including and 
excluding this data. We found that while the genes associated with the topics and clusters were 
generally functionally similar, this change in input data resulted in a different set of features 
being captured by the topics. This was highlighted by the fact that the two representations had 
different cancer types with significantly different survival results, and that the clusters had a 
much cleaner separation when using the driver data. The cleaner separation also indicates that 
driver data is useful for filtering out noise. Therefore, our results support the use of driver data in 
our methods. 
With the known limitations of semantic representations, we wanted to explore a more 
data-driven approach. This led to the development of a biological representation using the causal 
relationship between driver SGAs and differentially expressed genes (DEGs). To our knowledge, 
this is the first time a biological representation has been used to capture the functional 
information of genes or tumors. Our evaluation showed that this representation is capable of 
differentiating between functionally related and random genes. Application of topic modeling 
allowed us to identify topic association patterns that aligned with tissue of origin. When the topic 
associations was able to separate patients into groups with significantly different survival rates, it 
showed that, like semantic representations, biological representations could also be used to 
capture clinically relevant features. 
There are a number of limitations inherent to the studies, one of which is that the results 
are all dependent upon the quality and accuracy of the representations. As such, we tried to 
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ensure that the representations used were capable of capturing the functional similarity of genes. 
It still stands to reason that any improvements to the representation would only be beneficial to 
the overall results. The accuracy of the results is also dependent on the sample size available as 
input, as driver predictions and the generated topics only improve when sample sizes increase. 
Therefore, this methodology would not be appropriate for small sample sizes. Another limitation 
is the difficulty inherent in interpreting and comparing the biological relevance of topics 
generated through topic modeling. While gene enrichment tools can be used to evaluate gene 
lists associated with a topic, these lists are only readily available when using our biological 
representation. All other situations would require an extra extrapolation step to identify the genes 
associated with a topic. Even if a gene list is readily available, it is difficult to quantitatively 
compare gene enrichment results. This problem also directly ties in with another limitation. 
Without an accurate understanding of what the topics are representing, it is difficult to interpret 
the biological implications of the topic associations generated. 
Despite these limitations, the methodologies developed here show promise and are worth 
further investigation. While mainly limited to text data, topic modeling has been applied to 
biomedical data with an increasing frequency. Its ability to identify topics and associations 
directly from the data is useful when dealing with large datasets containing many features 
(words). If it turns out that the hierarchical tree generated using nHDP can capture the pathways 
involved in cancer and their relationships, then there is the potential for its use to help guide 
cancer treatment. This would allow treatments to be designed based on a patient’s perturbed 
signaling pathways obtained using their genomic data. 
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6.0 FUTURE WORK 
The work in this dissertation is an initial exploration into the applicability of alternative 
representations and topic modeling to the analysis of cancer genomic data. Following this work, 
there are two major directions that can be focused on in future work. One focus would be on 
improving or exploring different aspects related to the methodology that we have used. The 
second focus would be to apply this framework to other datasets. 
6.1 METHOD REFINEMENT 
One of the areas that requires additional work is developing a metric or method that can be used 
to analyze and evaluate the generated topics. While we have a method of measuring the 
coherency of the topics, this does not allow us to compare the functions associated with the 
topics. As such, without such a measure it is difficult to compare between the information 
captured using two different models.  
If such a measure was established, then this would allow for the exploration and 
evaluation of other aspects of the framework. It would be possible to evaluate the stability of the 
model, and determine how much the functions captured in a topic changes depending on the 
input data. For example, this would allow us to determine how the use of driver data changes the 
functions captured. Another aspect that could be explored would be how the use of different 
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topic models impact the functions captured. This would give us a better idea of how the 
hierarchical nature of the nested hierarchical Dirichlet process captures the relationship between 
functions in a way that flat topic models are unable to. 
Another aspect that could be refined would be the gene and tumor representations. After 
the first study, we made changes to the semantic representations used. However, there are still 
other potential knowledge sources that can be explored, and variations of the vector 
representations that can be used. On the other hand, we have not had a chance to explore the 
biological representation more fully. As such, it is possible that the representation could be 
improved through further adjustments. For example, setting a threshold that limits the number of 
differentially expressed genes used in the representation. This could potentially limit the tissue-
specific genes included, and also has the additional benefit of decreasing the vocabulary size. 
6.2 ADDITIONAL APPLICATIONS 
The other aspect that could be explored is applying these methods to other datasets. One area that 
can be explored is analyzing a subset of the cancer types. Since we were interested in seeing if 
there were functions shared across different cancer types, we mainly focused on pan-cancer data. 
However, it may also be of value to explore study cancer on a smaller scale, such as a specific 
cancer type, tissue of origin, or cell type. This is especially true for the current biological 
representation, which separates the tumors by cancer type. Studying a subset of cancer types 
would result in a more refined and detailed look at the subset being studied, which may make it 





A.1 SUPPLEMENTAL TABLES 
S Table 1. Survival analysis results of all five cancer types using semantic representation 
Cancer Type All Samples (P-Value) Minimum 25 Samples (P-Value) 
BRCA 0.00398 0.00093 
HNSC 0.0126 0.00701 
LUAD 0.456 N/A 
LUSC 0.038 0.0355 




S Table 2. Somatic mutation classifications and associated functional implications 















S Table 3. Number of tumors used for each cancer type in pan-cancer data 







Bladder urothelial carcinoma BLCA 234 200 
Breast invasive carcinoma BRCA 972 851 
Colon adenocarcinoma COAD 182 182 
Esophageal carcinoma ESCA 209 149 
Glioblastoma multiforme GBM 234 201 
Head and neck squamous cell carcinoma HNSC 491 459 
Kidney renal clear cell carcinoma KIRC 446 426 
Kidney renal papillary cell carcinoma KIRP 169 168 
Liver hepatocellular carcinoma LIHC 194 147 
Lung adenocarcinoma LUAD 465 383 
Lung squamous cell carcinoma LUSC 178 136 
Ovarian serous cystadenocarcinoma OV 449 322 
Prostate adenocarcinoma PRAD 419 398 
Rectum adenocarcinoma READ 81 77 
Stomach adenocarcinoma STAD 227 176 
Thyroid carcinoma THCA 399 N/A 
Uterine corpus endometrial carcinoma UCEC 239 193 





S Table 4. Proportion of topics meeting the PPI ratio threshold for semantic somatic genomic alteration dataset  
Threshold Count Percentage 
0.9 201 98.05% 
0.95 201 98.05% 




S Table 5. Proportion of topics meeting the PPI ratio threshold for semantic driver dataset 
Threshold Count Percentage 
0.9 177 90.77% 
0.95 177 90.77% 




S Table 6. Proportion of PPI ratios smaller than cluster gene list for semantic somatic genomic alteration dataset  
Cluster Proportion Smaller # of Genes 
1 1 25304 
2 1 31693 
3 1 23513 
4 1 26550 
5 1 23829 
6 1 25107 
7 1 23664 
8 1 14552 
9 1 16547 
10 1 3783 
11 1 23382 
12 1 19067 
13 1 14068 
14 1 20806 
15 1 10853 








S Table 7. Proportion of PPI ratios smaller than cluster driver list for semantic driver dataset 
Cluster Proportion Smaller # of Drivers 
1 0.9995 12 
2 0.9995 1937 
3 0.9977 1651 
4 1 126 
5 0.9867 371 
6 0.9994 1196 
7 0 13 
8 0.9948 1395 
9 1 974 
10 0.9961 1954 
11 0.9993 1330 
12 0.9705 329 
13 0.9999 1555 
14 0.9937 1307 
15 0.9979 484 
16 1 1071 
17 1 958 
18 1 1163 
19 0.9987 1027 
20 1 1122 
21 1 1132 
22 1 838 










S Table 8. Proportion of PPI ratios smaller than cluster gene list for semantic driver dataset 
Cluster Proportion Smaller # of Genes 
1 0.9864 540 
2 0.9951 15954 
3 0.492 15255 
4 0.0001 5849 
5 0 8428 
6 0 12623 
7 0.136 499 
8 0 12603 
9 0 11878 
10 0.0072 14644 
11 0.9977 15160 
12 0 8296 
13 0.0629 13769 
14 0.1309 14507 
15 0.2354 10988 
16 0.1929 13575 
17 0.0002 8451 
18 0 12793 
19 0.01 12315 
20 0.7802 13634 
21 0 12554 
22 0 11338 
23 0.0003 11843 
 
 
S Table 9. Proportion of topics meeting the PPI ratio threshold for biological driver dataset 
Threshold Count Percentage 
0.9 144 83.24% 
0.95 139 80.35% 





S Table 10. Proportion of PPI ratios smaller than cluster driver list for biological driver dataset 
Cluster Proportion Smaller # of Drivers 
1 1 2005 
2 1 1387 
3 0.9998 1416 
4 1 1589 
5 0.9983 1481 
6 0.9954 1243 
7 0.9999 1279 
8 1 1425 
9 1 1207 
10 1 1176 
11 0.9997 1450 
12 0.9998 1144 
13 1 1297 
14 1 879 














S Figure 1. Word vector length distributions. Distribution of the length of the gene word vectors 
generated using different semantic datasets. A) Pubmed articles, B) GeneRIFs, C) gene summaries, D) GeneRIFs 
and gene summaries 
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S Figure 2. Clustering of tumors using genomic alterations. Samples were clustered using genomic 











S Figure 4. Survival analysis of tumors for semantic SGA dataset. The survival analysis curves 
calculated using only the clusters that contain at least 20 samples. Figures A and B correspond to cancer types KIRC 













S Figure 5. Survival analysis of tumors for semantic driver dataset. The survival analysis curves 
calculated using only the clusters that contain at least 20 samples. Figures A, B, and C correspond to cancer types 
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